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Summary
The human Ewing Sarcoma (EWS) protein is a multifunctional RNA-binding protein, which 
plays a role in transcriptional activation, DNA pairing and repair, RNA splicing, and signal 
transduction. Beside its mainly nuclear localization, the EWS protein was also found to be 
associated with the cell membrane, but the mechanism mediating this association is unknown. 
In the family of Ewing sarcoma tumors, chromosomal translocation of the EWS gene results 
in the expression of fusion proteins of the EWS protein with one of several ETS 
(erythroblastostosis virus-transformed sequence) transcription factors. The transforming 
potential of such fusion proteins is repressed in the wild-type EWS protein by the presence of 
its C-terminal RNA-binding domain (RBD). In previous studies in our lab, the RBD was 
found to undergo extensively post-translational dimethylation at arginine residues within its 
arginine-glycin rich regions (RGG boxes 1-3). The contribution of the EWS protein in the 
above mentioned cellular processes as well as the function of the methylations are 
investigated within this study.
The first goal of this thesis was to identify the human protein arginine methyltransferases 
(PRMT) that catalyze the methylation of the EWS protein. Out of nine currently known 
PRMTs, the three PRMTs 1, 3, and 8, which catalyze the methylation of arginine residues 
within RGG motifs, were chosen to test for methyltransferase activity towards the EWS 
protein. PRMT1, the main methyltransferase in human cells, methylated the EWS protein 
almost completely in vitro (27 of total 30 methylation sites), as determined by mass 
spectrometry. The cytoplasmic PRMT3 and the membrane-associated PRMT8 methylated 
only nine and five arginine residues, respectively, mainly within the C-terminal RGG box 3 of 
the EWS protein. Although all 30 methylation sites are situated in highly similar RGG motifs 
(RGG boxes 1-3), structural determinants seem to hinder the accessibility of the RGG boxes 1 
and 2 for PRMT3 and 8, whereas the C-terminal RGG box 3 of the EWS protein is most 
accessible for PRMT3 and 8. Additionally, a method to determine so far unknown kinetic 
parameters of the PRMTs was developed by measuring the methylation of a synthetic peptide
with mass spectrometry. The catalytic efficiency of PRMT3 was found to be 12fold higher 
than that of PRMT1, whereas that of PRMT8 was 30fold lower, supporting the notion that 
structural rather than kinetic features of the substrate are responsible for the difference in 
EWS protein methylation by the PRMTs.
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The second part of this study shows that PRMT8, the only membrane-associated 
methyltransferase, interacts with several nuclear, RGG-containing proteins, like the RNA-
binding proteins EWS, TLS/FUS, and TAFII68, hnRNPs, and RNA-helicases. PRMT8 binds 
to the RGG box 3 of the EWS protein independent of its methylation state implying an 
additional role of PRMT8, beside its function as methyltransferase, as an adaptor protein for 
methylated nuclear proteins like the EWS protein at the membrane.
In the last part of this dissertation, the cellular role of the EWS protein, in particular that of 
the RBD and its multiple arginine methylations, was investigated by analyzing protein-protein 
interactions of unmethylated and methylated recombinant EWS protein. In these studies, co-
expression of the EWS protein or the RBD and PRMT1 in E. coli was successfully 
established resulting in complete methylation of the EWS protein or the RBD in bacteria. 
Protein complexes consisting of more than 30 different proteins, mainly heterogeneous 
nuclear ribonucleoproteins (hnRNPs) and RNA helicases, were found to co-purify with the 
unmethylated RBD of the EWS protein. The interaction with these RNase-sensitive 
complexes is mediated either by RNA-binding of the EWS protein or through direct 
interaction of the EWS protein with hnRNP M, U, and the RNA-helicases p68 and p72. Co-
precipitation and co-localization studies of the EWS protein and p68 did not only confirm 
their interaction, but showed also a re-localization of the EWS protein upon p68 expression 
from the nucleoplasm to the nucleolar periphery. Such re-localizations were observed for 
many nuclear proteins upon transcriptional inhibition. Remarkably, all these interactions did 
not depend on the methylation of the EWS protein although they take place in the extensively 
methylated domain of the EWS protein.
Methylation of arginine residues has been shown to regulate various cellular functions of 
proteins like their subcellular localization, functional activation/repression, and protein-
protein or protein-nucleic acid interactions. The present study shows that methylation of the 
EWS protein takes place shortly after translation or even co-translationally, as no
unmethylated EWS protein was found, be it in the nucleus, in the cytoplasm, or at the cell-
surface. A role of the methylation in the subcellular localization of the EWS protein can be 
excluded as the EWS methylation is not needed for the nuclear import. As described above,
arginine methylations are also dispensable for EWS protein-protein interactions. Thus, the 
methylation of the EWS protein has to play a role in other functions, such as RNA binding,
the fine-tuning of the activation/repression activity of the EWS protein, stabilization of the 
EWS protein against proteolysis, or it can serve as source for asymmetrically dimethylated 
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arginine, which is a regulator of nitric oxide synthase (NOS) in the cell. No demethylases are
known so far, and the extensive arginine methylation of the EWS might therefore have a static 
role rather than being a dynamic regulatory element of its function.
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Zusammenfassung
Das menschliche Ewing-Sarcoma (EWS)-Protein ist ein multifunktionales RNA-bindendes 
Protein, welches in diversen zellulären Prozessen wie der transkriptionellen Aktivierung, der 
Reparatur und Zusammenlagerung von DNA-Strängen, dem Splicing und der 
Signaltrasduktion eine Rolle spielt. Das EWS-Protein findet sich hauptsächlich im Zellkern, 
jedoch in geringeren Fraktionen auch an der Zellmembran. Es ist nach wie vor unklar, wie das 
EWS-Protein an der Zellmembran assoziiert ist. In Ewing-Sarkom-Tumoren führt eine 
chromosomale Translokation des EWS-Gens zu der Expression von Fusionsproteinen, 
bestehend aus der N-terminalen Domäne des EWS-Proteins (EAD) und der C-terminalen 
Domäne eines (von mehreren) ETS-Transkriptionsfaktoren. Die Expression solcher 
Fusionsproteine führt zur Transformation der Zelle und damit zur Tumor-Entstehung. In einer 
gesunden Zelle wird das Transformationspotential der EAD im Wildtyp-EWS-Protein durch 
die C-terminale RNA-bindende Domäne (RBD) unterdrückt. Vorhergehende Studien in 
unserem Labor haben gezeigt, das mehrere Argininreste in dieser RBD post-translational 
methyliert werden. Dies betrifft jedoch ausschliesslich Argininreste in Arginin-Glycin-reichen 
Regionen (RGG-Boxen). Die Funktion des EWS-Proteins in den oben genannten zellulären 
Prozessen wie auch der Beitrag der Methylierungen sind weitgehend unklar und deren 
Untersuchung ist Gegenstand dieser Studie.
Das erste Ziel dieser Arbeit war die Identifizierung von Protein-Arginin-Methyltransferasen 
(PRMT), welche die Methylierungen des EWS-Proteins katalysieren. Von bisher neun 
bekannten menschlichen PRMTs wurden die drei PRMTs 1, 3 und 8 für nähere 
Untersuchungen ausgewählt, da diese speziell die Methylierung von Argininresten in RGG-
Boxen katalysieren. Mittels Massenspektrometrie (MS) konnten wir zeigen, dass PRMT1, die 
vorherrschende Methyltransferase in der Zelle, das EWS-Protein fast vollständig methyliert 
(27 von total 30 methylierten Argininresten). Sowohl die cytosolische PRMT3 als auch die 
zellwand-assoziierte PRMT8 waren nicht in der Lage, das EWS Protein vollständig zu 
methylieren (nur neun bzw. fünf methylierte Arginine wurden detektiert). Obwohl die 
Aminosäuresequenzen sämtlicher 30 Methylierungsstellen des EWS Proteins sehr redundant 
sind, methylieren PRMT3 und 8 hauptsächlich Argininreste innerhalb der C-terminalen RGG-
Box 3. Offensichtlich erschweren strukturelle Domänen zwischen den RGG Boxen 1 und 2 
den Zugang für PRMT3 und 8. Zusätzlich wurde eine Methode zur Bestimmung bisher 
unbekannter kinetischer Parameter der PRMTs entwickelt, die ausschliesslich auf MS Daten 
eines in vitro methylierten Peptids beruht. Die katalytische Effizienz von PRMT3 ist demnach 
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um ein 12-Faches höher als die von PRMT1. PRMT8 dagegen hat eine 30-fach geringere 
katalytische Effizienz als PRMT1. Diese Daten unterstützen die Annahme, dass eher die 
Struktur des Substrats als kinetische Eigenschaften der Enzyme für die unterschiedlichen 
EWS-Methylierungen verantwortlich ist.
Im zweiten Teil dieser Studie wird gezeigt, dass die zellwand-assoziierte PRMT8 mit 
diversen Kernproteinen, wie z.B. den RNA-bindenden Proteinen EWS, TLS/FUS, und 
TAFII68, mit heterogenen nuclearen Ribonukleoproteinen (hnRNPs) und RNA-Helikasen 
interagiert. Die Wechselwirkung zwischen PRMT8 und der C-terminalen RGG-Box 3 des 
EWS-Proteins findet unabhängig vom Methylierungsgrad des EWS-Proteins statt. Es lässt 
sich daher vermuten, dass PRMT8 neben seiner Funktion als Methyltransferase eine 
zusätzliche Rolle als Adapterprotein für methylierte Kernproteine an der Zellmembran 
einnimmt.
Im letzten Teil dieser Dissertation wurde die zelluläre Funktion des EWS-Proteins, 
besonders seiner RBD einschliesslich der methylierten Argininreste, untersucht, indem 
interagierende Proteine des unmethylierten und des methylierten rekombinanten EWS-
Proteins bestimmt wurden. Dafür wurde erfolgreich eine Co-Expression des EWS-Proteins 
oder der RBD und PRMT1 in Bakterien etabliert, womit bereits methyliertes rekombinantes 
EWS-Protein bzw. RBD in Bakterien hergestellt werden kann. Mehr als 30 verschiedene 
Proteine, darunter hauptsächlich hnRNPs und RNA-Helikasen, konnten als 
Interaktionspartner der unmethylierten RBD des EWS-Proteins identifiziert werden. Die 
Wechselwirkungen des EWS-Proteins mit diesen RNase-empfindlichen Protein-Komplexen 
wird entweder über eine Wechselwirkung des EWS-Proteins mit RNA oder über eine direkte 
Bindung zu den Proteinen hnRNP M und U, sowie den RNA-Helikasen p68 und p72, die als 
direkte Interaktionspartner identifiziert worden sind, erhalten. Die Wechselwirkung zwischen 
p68 und p72 mit dem EWS-Protein wurde durch Co-Präzipitationen sowie durch Co-
Lokalisierung in HEK-Zellen bestätigt. Dabei konnte gezeigt werden, dass sich das EWS 
Protein bei einer Co-Expression mit p68 vom Kern-Plasma zur Peripherie der Nucleoli 
verschiebt. Bei gehemmter Transkripition wurde eine solche Umlagerung bereits bei 
mehreren anderen Kernproteinen beobachtet. Bemerkenswert ist, dass eine Methylierung des 
EWS-Proteins keinerlei Einfluss auf die Protein-Wechselwirkungen hat, obwohl sämtliche 
hier gezeigten Wechselwirkungen mit der RBD des EWS-Proteins stattfinden, die sämtliche 
Methylierungsstellen enthält.
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Die Arginin-Methylierung von Proteinen kann mannigfaltige Prozesse wie z.B. die 
intrazelluläre Lokalisierung von Proteinen, die funktionelle Aktivierung oder Repression von 
Enzymen, oder die Wechselwirkungen zwischen Proteinen oder Proteinen und Nucleinsäuren 
steuern. Diese Studie zeigt, dass das EWS-Protein bereits kurz nach oder sogar während der 
Translation methyliert wird, da in der Zelle bisher kein unmethyliertes EWS-Protein 
nachgewiesen werden konnte, weder im Zellkern, noch im Cytosol oder an der Zellmembran. 
Eine Funktion des Methylierungsgrades in der subzellulären Lokalisierung des EWS-Proteins 
kann ausgeschlossen werden, da sowohl methyliertes als auch unmethyliertes EWS-Protein in 
den Zellkern transportiert wird. Wie oben beschrieben, sind die Arginin-Methylierungen des 
EWS-Proteins ebenfalls für Protein-Protein-Wechselwirkungen verzichtbar. Verbleibende 
mögliche Funktionen der Methylierungen des EWS-Proteins sind daher zum Beispiel die 
Modulation von Interaktionen zwischen RNA und dem EWS-Protein, die Steuerung der 
Aktivierungs-/Repressions-Aktivitäten des EWS-Proteins, die Stabilisierung des EWS-
Proteins gegen proteolytische Degradierung oder aber als Quelle für asymmetrisch 
dimethyliertes Arginin, welches in der Zelle das Enzym Nitroxid-Synthase (NOS) reguliert. 
Da bis jetzt noch kein Enzym bekannt ist, welches eine Demethylierung katalysiert, ist eher 
eine statische Rolle der Methylierungen als eine regulatorische Funktion der EWS-Aktivität 
denkbar.
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1. General Introduction
Post-Translational Modifications
In 1990, the human genome project was started with the goal to sequence all human 
chromosomes. This goal was achieved and it turned out, that the human organism has only 
20000 to 25000 protein-coding genes (2). This rather small number of genes was unexpected, 
as the insect Drosophila melanogaster has already ~13500 genes and even the bacterium 
Escherichia coli with ~5000 genes has only a 4 fold smaller genome than human. An increase 
in complexity in higher eukaryotes is achieved at several levels of the protein biosynthesis. 
Various genes undergo alternative splicing after transcription, or different promoters for the 
same gene are used resulting in an estimated transcriptome of ~100000 human transcripts 
which is already a four- to five-fold increase in complexity. Another ten-fold increase in 
complexity is the result of post-translational modifications (PTMs). Once the protein is 
synthesized, manifold modifications like the cleavage of pro-peptides, the attachment of 
chemical groups (phospho-, acetyl-, or methyl groups, sugars, lipids, etc.) or internal and 
external cross-linking of polypeptide chains can direct the function of the protein. Taking 
such PTMs into account, the human proteome is by now estimated to contain more than 
1000000 different proteins (3).
Therefore, the characterization of post-translational modifications and their responsible 
enzymes is necessary to understand the diversity of protein functions in the cell.
In this thesis, protein arginine methylations and its catalyzing enzymes were investigated in 
detail. Although this eukaryotic post-translational modification and its catalyzing enzymes are 
essential for the survival of the cell, it is hardly described in current biochemistry text books. 
The following chapter gives an overview about this in my opinion underestimated 
modification.
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Figure 1.1: (A) Methylation of the arginine side chain by PRMTs. All PRMTs catalyze the formation of 
monomethyl-arginine (MMA), where the methyl donor S-adenosly-L-methionine (AdoMet) is converted to S-
adenosyl-L-homocysteine (AdoHcy). In a second step, the type I PRMTs transfer a second methyl group to the 
same guanidino nitrogen resulting in an asymmetric dimethylarginine (ADMA) whereas the type II PRMTs 
catalyze the formation of symmetric dimethylarginines (SDMA). (B) Overview of the human PRMT family. The 
length of each protein is indicated by the numbers of amino acids. The PRMTs 1-8 all have a conserved AdoMet 
binding domain (shaded in grey) with the conserved motifs I, post I, II, and III, and a less conserved substrate 
binding domain (light grey). The conserved motifs I, post I, II, and III are present as well in PRMT 9, but the 
whole AdoMet binding domain shares only little homology to the other members of the PRMT family.
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Protein Arginine Methylation
(summarized Review: “Steffen Pahlich, Rouzanna P. Zakaryan and Heinz Gehring. Protein 
arginine methylation: Cellular functions and methods of analysis. Biochim Biophys Acta. 
2006 Dec;1764(12):1890-903.”)
Arginine methylation is a common post-translational modification of mainly nuclear 
proteins in eukaryotic cells, and is catalyzed by a family of enzymes called protein arginine 
methyltransferases (PRMTs). S-Adenosyl-L-methionine (AdoMet) is used as the methyl 
donor in this reaction where the methyl group is transferred to one of the guanidinium 
nitrogens of arginine residues. PRMTs are classified into two groups. While type I PRMTs 
catalyze the formation of NG-monomethylarginine (MMA) and asymmetric ω-NG, NG -
dimethylarginine (ADMA), type II enzymes form MMA and symmetric ω- NG, N’ G -
dimethylarginine (SDMA,Fig 1.1 A).
Although arginine methylation was 
discovered more than 30 years ago (4,5), 
the responsible enzymes and the wide 
variety of substrates were largely 
unknown. In 1996, the first PRMT 
genes were cloned (6,7) and from then
on, large quantities of pure and active 
recombinant enzyme was available for 
functional studies. Genetic screening 
yielded the identification of further 
PRMT genes and the knowledge and 
understanding of this modification 
increased steadily as indicated by the 
increase of scientific publications about 
arginine methylations from 1996 on 
(Fig. 1.2).
Members of the PRMT family were found in many different eukaryotes from protozoa and 
fungi to higher plants and animals as highly conserved enzymes (8,9). Currently, nine human 
protein arginine methyltransferases are known: the type I methyltransferases PRMT1, PRMT3, 
PRMT4 (CARM1), PRMT6, and PRMT8, and the type II enzymes PRMT5, PRMT7, and 
Figure 1.2: Scientific publications about arginine 
methylations from 1990 until 2006. The numbers 
were achieved using the PubMed database 
(http://www.ncbi.nlm.nih.gov/) and the search 
terms “arginine methylation” and the 
corresponding year.
First recombinant 
PRMT
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Substrate Substrate
53BP1 GST-GAR
CIRP EWS
EWS Sam68
FGF-2 PABP II
Fibrillarin hnRNP A1
FKBP 12 rpS2
Fmrp
GRP33 CARM1
GST-GAR Histone H3
GRY-RBP PABP1
Hepatitis C virus NS3 Helicase p300/CBP
Hepatitis delta antigen S-HDAg TARPP
Histone H4 ILF3
hnRNP A1 HuR
hnRNP A2 HuD
hnRNP K
hnRNP R Squid
ILF3 Vasa
Mre 11
NF 90 Histones H4, H2A, H3
NIP45 MBP
Nucleolin Sm D1
p137GP1 Sm D2
PABP II SM B/B´
?????? coilin
QKI-5 LSm4
RBP58 EBNA-2
RNA helicase A SPT5
SAF-A (hnRNP U)
Sam68 PRMT6
SAMT1 GST-GAR
SLM-1 Np13
SLM-2 HIV Tat
SPT5 HMGA1a
TAFII68 DNA polymerase beta
TIS21/BTG2
TLS/FUS GST-GAR
ZF5
Gar1p GST-GAR
Hrp1 GST-Npl3
Nab2p Histone H4
Nor1p
Npl3 not determined
Nsr1p
Yra1
not determined Vav-1
Myosin
Herpes simplex virus ICP27
Adenovirus hnRNP E1B-AP5 RBP16
Golgi proteinsnot determined
PRMT1 (type I),                         
nuclear & cytoplasmic
HMT1 (yeast homolog),              
nuclear & cytoplasmic
PRMT3 (type I),                  
cytoplasmic
PRMT4/ CARM1 (type I),               
nuclear
DART4 (Drosophila homolog),  
 nuclear
PRMT5 (type II),                      
nuclear & cytoplasmic
PRMT6 (type I),                         
nuclear
PRMT7 (type I),                   
nuclear & cytoplasmic
PRMT8 (type I),               
membrane-associated
not determined
not determined
not determined
not determined
PRMT9 (type II),                    
nuclear & cytoplasmic
Table I: known substrates and intracellular localization of the PRMTs
 
PRMT2 (type I),                        
nuclear & cytoplasmic
HRMT1L1 (yeast homolog),                           
 nuclear
PRMT,                                 
intranuclear localzation
PRMT,                                  
intranuclear localzation
General Introduction – Arginine Methylation 17
PRMT9. PRMT2 was identified by sequence homology, however, as yet no 
methyltransferase activity could be determined (10) (Table I). Some homologues from other 
species are also listed in the table. Crystal structure analysis revealed a strong structural 
conservation of the AdoMet-binding site of different PRMTs (for reviews, see (11,12)) which 
however differ in N- and C-terminal extensions (Fig. 1.1 B). PRMT9 structurally differs from 
all other known PRMTs, implying convergent evolution of enzymic mechanism of arginine 
methylation (13).
PRMT1, the main methyltransferase in human cells with a wide substrate spectrum, is 
responsible for more than 80% of cellular PRMT activity (14). It generally recognizes 
arginines within a glycine-arginine-rich (GAR) region, a motif which is present in many 
RNA- or DNA-binding proteins. The other type I enzymes PRMT3, 6, and 8 also recognize 
GAR motifs whereas for PRMT4/CARM1 no preferred methylation motif is known. The type 
II enzymes PRMT5 and 7 methylate GAR motifs as well as arginines situated not in a known 
consensus region. Many methylated proteins have been identified to date, but the responsible 
methyltransferases are still largely unknown. The known substrates as well as the different 
subcellular localizations of the PRMTs are summarized in Table I.
Arginine methylation and protein function 
Arginine methylation is implicated in many cellular processes including transcription, RNA 
processing and transport, translation, signal transduction, DNA repair, apoptosis etc. In the 
following, the main functions are summarized.
Transcriptional regulation
Methylation of nucleosomal histones by PRMTs plays an important and dynamic role in 
nuclear receptor-mediated transcriptional regulation, chromatin remodelling and other aspects 
of gene expression (reviewed in (11,15)). Linkage of histone arginine methylation, lysine 
methylation, acetylation, phosphorylation and ubiquitination, regulates binding of specific 
interacting proteins, altering chromatin structure and transcription process (16).
Arginine methylation participates also in the regulation of the initiation and elongation steps 
of transcription. The methylation of the histone acetyltransferase CREB binding protein 
(CBP), which functions with the related p300 protein as a key transcriptional coactivator, by 
CARM1 blocks its CREB activation (17,18). PRMT1 and PRMT5 have been shown to 
methylate the transcriptional elongation factor SPT5 and thus to regulate its interaction with 
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RNA polymerase II (19), and arginine methylation by PRMT6 inhibits the transactivation
activity of HIV Tat protein, therefore PRMT6 acts as a restriction factor for HIV replication 
(20).
RNA processing and export; protein translation
RNA-binding proteins (RBPs) participate in processing, folding, stabilization and 
localization of RNAs and mRNA translation. Most of RBPs possess GAR motifs, and are 
well-known or putative substrates for PRMTs. Arginine residues in the binding sites of RBPs 
have been recognized as key amino acids in RNA-protein interactions and its methylation can 
facilitate as well as repress the interaction with RNA. 
It was demonstrated in yeast, that methylation activity is needed for the recruitment of 
mRNA-export factors during transcriptional elongation (21) and ribosome biosynthesis (22). 
Methylation of the RNA-binding proteins HuD (23) and HuR (24) by CARM1 has been 
shown to regulate their function in stabilization of specific mRNAs which is important in cell 
proliferation and differentiation. Arginine methylation of several RNA-binding proteins is 
needed for their proper subcellular (nuclear) localization (25,26) as demonstrated for SAM68
(27), hnRNP A2 (28), or hnRNP Q (29).
Signal transduction
Cell signaling is controlled by posttranslational modifications that alter protein-protein 
interactions. More and more data show that also arginine methylation is used to mediate 
signal transduction downstream of the TCR (T-cell antigen receptor), cytokine (including 
interferon), and NGF receptors (for reviews, see (8,30)).
DNA repair
53BP1, a central mediator of the DNA damage checkpoint, is rapidly recruited to sites of 
DNA double-strand breaks. Whereas oligomerization of 53BP1 was shown to be independent 
of methylation (31), asymmetric dimethylation of the GAR motif of 53BP1 by PRMT1 was 
demonstrated to be required for DNA binding activity (32). PRMT6 was found to play a 
direct role in the regulation of DNA repair p?????????????????????????????????????????????
which participates in base excision repair (33).
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Protein-protein interactions
Arginine methylation can increase or decrease protein-protein interactions. The methylation 
of an arginine residue of the HIV-1 Nef protein or hnRNP K inhibits their interaction with 
tyrosine kinases Fyn and c-Src, respectively (34), (35), and methylation of Sam68 prevents its 
association with SH3 domains. On the other hand, the interaction between the nuclear factor 
of activated T cells (NF-AT) and the NF-AT-interacting protein of 45 kD, NIP45, decreased 
in the presence of methylase inhibitors ((8) and references therein). 
Arginine protection
In addition to the above mentioned functions, it was proposed that arginine methylation 
might protect crucial arginine residues against attack by endogenous reactive dicarbonyl 
agents, such as methylglyoxal and other natural by-products of normal metabolic pathways 
(36). An experimental confirmation, however, is still missing.
Arginine methylation as a source of free MMA, ADMA and SDMA
Proteolysis of methylated proteins is the cellular source of free mono- and dimethylarginine 
residues. MMA and ADMA are known to be endogenous competitive inhibitors of nitric 
oxide synthase (NOS), which synthesizes NO from L-arginine, and plays an important role in 
cardiovascular system. Dimethylarginine dimethylaminohydrolases (DDAHs) specifically 
hydrolyze MMA and ADMA, but not SDMA. Deregulated levels of these free 
methylarginines affects NOS activity and, consequently, may result in cardiovascular disease 
((37) and references therein). 
Demodification of methylated arginines
Over the years, arginine methylation has been considered to be an irreversible 
posttranslational modification. The search for arginine demethylases did not yield any results. 
Nevertheless, the fact that lysine demethylases such as LSD1 have been identified makes it 
possible that arginine demethylases may also exist. Two groups showed that arginine 
methylation of histones can be reduced in vitro by deimination with PAD4 (38,39). This 
reaction converts both unmodified arginine and monomethylarginine, but not 
dimethylarginine, to citrulline, an amino acid that is not transcriptionally incorporated into 
proteins. However, dimethylated arginines, which is the dominant methylated amino acid in a 
cell extract (~70%), can not be converted to citrulline, and enzymes, catalyzing the conversion 
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from citrulline back to arginine are also unknown. Therefore, deimination is rather the 
exception than the rule in arginine demethylation.
Methods to detect and identify arginine methylated proteins and their 
methylation sites
In vitro methylation with [3H]-AdoMet
A common way to analyze arginine methylation is the in vitro methylation by using 
recombinant methyltransferases, radioactively labeled S-adenosyl-L-[methyl-3H]-methionine 
([3H]-AdoMet), and purified proteins or cell extracts as substrate. The labeled methyl groups 
are transferred to the substrates and can be detected by fluorography (40). However, in 
eukaryotic cells most methyl-accepting sites are occupied indicating that methylation occurs 
soon after translation (41,42) and untreated cell extracts are not suitable as substrate. To 
obtain free methylation sites of methyl accepting proteins, cellular protein methyltransferases 
are usually inhibited by adenosine dialdehyde (AdOx). AdOx inhibits S-adenosyl-L-
homocysteine hydrolase, leading to an accumulation of intracellular S-adenosyl-L-
homocysteine, which in turn is a product inhibitor of the methyltransferases (43). Cells treated 
with AdOx accumulate newly synthesized unmethylated methyl-accepting proteins during the 
incubation period (42,44) and can be used as substrate for in vitro methylations. However, one 
has to consider that the expression level of originally methylated proteins might be affected 
by the inhibitor treatment (45). Due to the incorporation of the labeled methyl group, 
methylation activity of the used enzyme can be detected by fluorography after separation of 
the proteins by SDS-PAGE. Using hypomethylated cell extracts, different substrates as well 
as substrate specificities of the PRMTs were observed with this method (46-50). It is easy and 
rapid to detect or proof methyltransferase activity of PRMTs against single substrate proteins 
or hypomethylated cell extracts. However, when hypomethylated cell extract is used as 
substrate, an identification of unknown methylated proteins is difficult and no information 
about the position of the methylated arginines within the proteins can be gained. 
Identification of the type of methylation by amino acid analysis
The type of methylation, namely MMA, ADMA, or SDMA, can be distinguished by amino 
acid analysis of the methylated sample. The methylated proteins or peptides have to be 
hydrolyzed completely and the resulting amino acids have to be separated 
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chromatographically (51,52). MMA, ADMA, and SDMA differ in their retention times or Rf-
values and can be assigned with the corresponding standards.
Detection of methylated arginines by antibodies
The different types of arginine methylation can also be analyzed by Western blotting using 
methyl-arginine-specific antibodies. This technique was used to identify the asymmetric 
dimethylation of the histones H3 and H4 (53,54), or SAM68 (27), the symmetric 
dimethylation of coilin (55), or the conversion of unmodified or monomethylated arginines in 
H3 and H4 to citrulline by PAD4 (38,39).
Commercially available antibodies (SYM10, SYM11, ASYM24 from Upstate or 7E6 from 
Abcam) are derived from synthetic peptides of several RG-repeats including either SDMA or 
ADMA (55) or as in the case of histones from a peptide covering the exact sequence 
including the modified arginine (38). These antibodies do not necessarily recognize all and 
only methylated proteins. With the 7E6-antibody, cross-reactivities could not be excluded 
(42), and also the specific recognition of methylated STAT1 and STAT3 by antibodies is 
questionable (56). So for each analysis, the specificity of the used antibodies has to be tested.
Detection of methylated arginines by mass spectrometry (MS) 
MS has become a favorable method not only to identify proteins by peptide mass fingerprint, 
but also to characterize post-translational modifications of proteins. Methylation leads to a 
mass increase of 14 Da per incorporated methyl group at the arginine residue. After enzymic 
digestion of a methylated protein, the mass shift can be used to find peptides that potentially 
contain this modification (Fig. 1.3) either in endogenously methylated proteins purified from 
a cell extract (57,58) or after in vitro methylation of recombinant unmodified proteins with 
different PRMTs (59,60). Arginine methylation does not change the ionization properties of 
the modified peptide and therefore, the detection of unmodified and modified peptides by 
MADLI-TOF-MS is not influenced by this modification. To confirm and detect the 
methylated amino acid, the corresponding peptide can be sequenced by MSMS. A specific 
fragment ion at m/z 46.06 corresponding to dimethylammonium is exclusively generated from 
the fragmentation of ADMA-containing peptides and can be thus used as a specific reporter 
ion for the detection of ADMA (61,62).
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Proteome analysis of arginine methylated proteins
The methods described above are mainly suitable for the characterization or identification of 
single proteins and their modifications. For a proteomic approach, however, the whole 
proteome or subproteomes like the phosphoproteome (selective enrichment of phosphorylated 
proteins) of an organism or cell type needs to be analyzed. Enrichment and analysis of a 
“methyl-proteome”, however, is difficult because the incorporation of methyl groups to the 
arginine side chain changes the physicochemical properties of this residue only slightly. 
Although the hydrophobicity is enhanced, the charge remains unchanged and methylated 
proteins or peptides can not be separated, so far, from unmodified ones by any 
chromatographic method as e.g. phosphoprotein or -peptide enrichment by immobilized metal 
affinity chromatography (IMAC).
In the following, methods are described to enrich or visualize methylated proteins for a 
“methyl-proteome” analysis.
In vivo methylation with [3H]-AdoMet
Yeast cells are capable to take up the methyl donor AdoMet from the medium (63). Proteins 
from yeast cells, grown in [3H]-AdoMet-containing medium were separated by 1D or 2D gel 
electrophoresis and the methylated proteins were detected by fluorography (64). AdoMet-
based methylation of lysines, histidines, or nucleic acids leads also to radioactive labeling. In 
rat cells, however, it has been shown that almost 90% of methylated amino acids of the cell 
Figure 1.3: Detection of protein arginine methylation by peptide mass fingerprints. Potential methylation 
sites of a protein can be identified by peptide mass fingerprint. Here, recombinant (unmethylated) human 
EWS protein was in-gel digested and analyzed by MALDI-TOF MS. The same was done with recombinant 
EWS protein, prior methylated with PRMT1. Methylation leads to a mass shift of multiples of 14 Da of 
peptides containing potential methylation sites like RGG motifs.
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extract are mono- and asymmetrically dimethylated arginines (65). If one considers a similar
proportion of methylated amino acids in yeast, methylation of other residues than arginines is 
expected to be a minor problem. The in vivo labeling, however, is limited to the analysis of 
protein methylation in yeast, because most other eukaryotic cells have only a poor uptake 
efficiency of AdoMet (66).
Instead, Najbauer et al. (65) used a hypomethylated cell extract of PC12 rat cells to 
visualize methyl acceptor proteins. PC12 cells were incubated in culture prior to lysis with 
AdOx, and [3H]-AdoMet was then added to the cell extract to methylate the proteins by 
endogenous methyltransferases present in the extract. The proteins were separated by 2D gel 
electrophoresis and more than 50 different methyl acceptor proteins, mainly basic proteins, 
could be detected by fluorography. However, an identification of these proteins was not 
possible and methylation of hypomethylated cell extracts might not reflect the “methyl-
proteome” of normally grown cells.
To avoid hypomethylation, cells can be incubated in methionine-free medium containing 
labeled methionine in the presence of protein synthesis inhibitors like chloramphenicol and 
cycloheximide. The labeled methionine is taken up by the cells and converted intracellularly 
into the labeled methyl-donor AdoMet. The incorporation of the labeled methyl group to a 
protein is due to the AdoMet-based methylation process and not due to incorporation of 
labeled methionine into newly synthesized proteins. With this method, Liu et al. (67)
discovered the methylation of numerous heterogeneous nuclear ribonucleoproteins (hnRNPs) 
by immunopurification and 2D gel electrophoresis of hnRNP complexes and detection of the 
labeled methylated hnRNPs by fluorography.
Immunopurification of methylated proteins
Boisvert et al. (68) used antibodies derived against synthetic peptides containing either 
SDMA or ADMA in different RG-rich motifs (see above) to immunoprecipitate methylated 
proteins out of a HeLa cell extract. The precipitated protein complexes were digested and 
more than 200 proteins were identified by LC/MSMS sequencing of the peptides. Proteins 
were assumed to have methylated arginines if they contain GAR-motifs within their amino 
acid sequence but were absent in a control experiment. Peptides containing methylated 
arginine residues, however, were not directly identified. Discrimination between potential
asymmetric or symmetric dimethylated proteins was based on the used antibodies and 
discrimination between methylated and co-purified unmethylated proteins was not possible.
General Introduction – Arginine Methylation 24
Ong et al. (69) introduced heavy methyl SILAC (stable isotope labeling by amino acids in 
cell culture) to identify methylated proteins from cell extracts. Cells were grown in medium 
containing either “light” (CH3)- or “heavy” (
13CD3)-methionine, which is taken up by the cells 
and metabolically converted to labeled AdoMet, used for intracellular methylation events. 
Both samples were combined in a 1:1 ratio, subjected to a single immunopurification step 
with specific antibodies (see above), digested, and analyzed by high mass accuracy 
LC/MSMS. The incorporation of one “heavy” methyl group leads to a mass increase of 4 Da 
compared to the “light” one. Thus, ion pairs with equal intensity ratios and distances 
corresponding to the incorporation of one or multiple methyl groups (e.g. 4 Da for MMA, 8 
Da for DMA) are hints for methylation. Peptides with such ion pairs were sequenced by 
MSMS to identify the position of the methylated arginine residues. With this promising 
method, both, identification and relative quantification of the methylation site are feasible. 
However, to reduce sample complexity, an immunopurification step with antibodies against 
methylated arginines was performed, and only 33 methylated proteins out of a whole HeLa 
cell extract were identified in this study. This modest enrichment of methylated proteins again 
reflects the moderate specificity of currently available antibodies against methylarginines for 
immunoprecipitation of the “methyl-proteome”.
In summary, a variety of methods for the analysis of protein arginine methylation are 
currently available, especially for in vitro studies. A complete “methyl-proteome” analysis 
can reveal the number of methylated proteins in the cell and give an idea of the variety of 
cellular processes this modification is involved in, but this approach remains a challenge. 
High throughput mass spectrometry makes it possible to identify huge amounts of different 
proteins and peptides in a short time, but there is still a lack of methods in efficiently 
enriching methylated proteins out of a whole proteome.
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The Ewing Sarcoma (EWS) Protein
The human Ewing sarcoma (EWS) protein, a multifunctional RNA-binding protein, was 
found in previous studies to contain multiple asymmetrically dimethylated arginine residues 
within its RNA-binding domain (RBD) (57). The functional role of this modification as well 
as the responsible methyltransferases, not known so far, was investigated in this study. In the 
following, the current knowledge about the structure and function of the EWS protein is 
summarized.
EWS protein and cancer
The human EWS gene is located at the chromosome 22 (22q12) and codes for the 656 amino 
acid long Ewings sarcoma (EWS) protein. In Ewing sarcoma family of tumors (ESFT) a part 
of the EWS gene is translocated resulting in the expression of fusion proteins between the N-
terminal transcriptional activation domain (EAD) of the EWS protein and the DNA-binding 
domain of one of several members of the ETS (erythroblastostosis virus-transformed 
sequence) transcription factors (70). ESFT are the second most malignant neoplasm of bone 
among children and adolescents. The most frequent chromosomal translocation 
t(11;22)(q24;q12) results in the expression of the oncoprotein EWS/Fli1 (90-95% within 
ESFT) (71), but also other cancer-associated gene fusions involving the EWS gene, like 
EWS/ATF1 (malignant melanoma of soft parts) (72), EWS/WT1 (desmoplasmic small round-
cell tumors) (73,74), or EWS/CHOP (myxoid liposarcoma) (75) are observed. In all cases, the 
fusion proteins act as transcriptional activator, modulating the expression of target genes 
different from those recognized by the proto-oncoproteins (70), but the detailed mechanism of 
transformation by EWS fusion proteins is still open.
In the wild-type EWS protein, the transforming potential of the EAD is repressed by the C-
terminal RNA-binding domain (RBD) (76), but the mechanism and the cellular function of 
the proto-oncoprotein EWS in general is largely unknown. The determination of the cellular 
role of the wild type EWS protein will therefore contribute to the understanding of the tumor-
associated transformation by EWS fusion proteins.
Structure of the EWS protein
The EWS protein consists of two functional domains, an N-terminal transcriptional 
activation domain (EAD) and a C-terminal RNA-binding domain (RBD,Fig. 1.4).
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N-terminal transcriptional activation domain (EAD)
The N-terminal transcriptional activation domain (EAD, AA 1-299) of the EWS protein is 
composed of multiple degenerated hexapeptide repeats (DHR) with the consensus sequence
SYGQQS including a highly conserved Tyr residue. The EAD of the EWS protein does not 
possess any secondary or ternary structure and due to its amino acid composition, it is most 
likely an intrinsic disordered domain. A prediction of intrinsically disordered regions using 
PONDR (Predictor of Naturally Disordered Regions, www.pondr.com) revealed ~80 % of the 
EWS protein to be disordered, including the whole EAD (77). The amino acids 258-280 build 
an IQ domain, which binds calmodulin and can be phosphorylated by protein kinase C (78).
C-terminal RNA-binding domain (RBD)
The C-terminal RNA-binding domain (RBD, AA 300-656) of the EWS protein consists of 
an RNA-recognition motif (RRM, AA 361-447) and a putative C2C2 zinc finger (AA524-543),
surrounded by arginine-glycine rich regions (RGG-box 1-3). Finally, the last 17 amino acids 
define a new nuclear localization signal (C-NLS), as recently discovered in our lab (79) and 
elsewhere (80).
RNA-recognition motif (RRM)
RNA-recognition motifs (RRM) are well known domains of RNA- or DNA-binding 
proteins. This motif is one of the most abundant protein domains in eukaryotic proteins. By 
now, approximately 6000 RRMs were found in ~ 3500 different proteins, and 2% of the 
Figure 1.4: Structural and functional motifs of the EWS protein. The abbreviations used are: EAD, N-
terminal transcriptional activation domain; RBD, RNA binding domain, DHR`s, degenerated hexarepreats 
with the consensus sequence SYGQQS; IQ, IQ domain which binds calmodulin; RGG, arginine-glycine 
rich regions; RRM, RNA-recognition motif; ZF, putative C2C2 zinc finger motif; NLS, nuclear localization 
sequence.
RGG 1 RGG 2 RGG 3RRM ZF
RBDEAD
IQDHR`s
NLS
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human gene products contain one or several RRMs. Recently, RRMs were also identified in 
prokaryotic proteins (85 proteins in bacteria, mainly cyanobacteria, and six proteins in 
viruses), but their roles in bacteria and viruses is still unknown (81).
RRMs consist of an???-???????????????????????????1α1?2?3α2?4?????????????????????????????-
sheets form a flat surface which serves as docking platform for RNA or DNA. The two α-
????????????????????????????????-sheets whereas the N- and C-terminal regions of the RRM are 
unstructured linker. The interaction between the RRM and nucleic acids is maintained by 
three highly conserved aromatic amino acids (Phe or Tyr) ????????????-sheets 1 and 3, which 
interact hydrophobically with the bases of the nucleic acids. The high affinity and sequence 
specificity of different RRMs towards their RNA- or DNA targets is achieved by the 
assistance of the e?????????-???????????????????????????????????????-sheets and the α-helices, 
or by the association of multiple RRMs (81).
The structure of the EWS-RRM was solved by NMR (Nagata et al. 2005, Research 
Collaboratory for Structural Bioinformatics (RCSB) database (www.rcsb.org), unpublished 
data?????????????????????????-sheet platform and the two α-helices (Fig. 1.5 A). Interestingly, 
a sequence alignment with the RNA-binding protein hnRNP A1 shows, that the two aromatic 
?????? ?????? ??? ?-sheet 3, responsible for RNA-binding via hydrophobic interaction, are 
replaced in the EWS RRM (and its homologues TLS/FUS and TAFII68) by a threonine and an 
aspartic acid (Fig. 1.5 A). In vitro RNA-binding activity of the EWS protein was 
demonstrated towards poly G- and poly U-RNA via its C-terminal RGG box (82), however, 
no direct binding of RNA or DNA to the EWS RRM was demonstrated yet. RRMs are also 
known to mediate protein-protein interaction, as it was demonstrated for the exon-junction 
complex protein Y14, which interacts via its ?-sheet surface of the RRM with magoh (83). 
The RRM of the EWS homolog TLS was found to be dispensable for RNA binding in vivo
(84), and in vitro (85). Thus, it is reasonable, that the RRM of the EWS protein (and its 
homologues) might serve to maintain rather protein-protein than protein-RNA interactions.
Zinc finger motif (ZF)
The RBD of the EWS protein contains a putative C2 C2 zinc finger motif, also called RanBP 
zinc finger due to its homology to the nuclear export protein RanBP2 zinc finger. Such zinc 
finger motifs sandwich a single zinc atom by two sho????-hairpins. The RanBP zinc finger of 
ZNF265 was found to bind mRNA (1), the one of Npl4 interacts with ubiquitin (86), and the 
TLS/FUS zinc finger is able to bind a GU-rich RNA oligomer (85). The functional role as
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Figure 1.5: (A) NMR structure of the RNA-recognition motif of the EWS protein (Nagata et al., 2005, 
unpublished data). The sequence alignment of the hnRNP A1 RRM and the RRMs of the TET family proteins 
was done with ClustalW. The th???? ????????? ?????? ?????? ??? ???????????????? ??? ??????? ???????? ??? ???? ????
?????????? ???? ???? ????????????? ??? ???? ??? ??? ???? ???-family proteins EWS, TLS, and TAFII68, the aromatic 
amino acids are replaced by aspartic (or glutamic) acid and threonine. (B) Homology model of the EWS zinc 
finger structure based on the known NMR structure of ZNF265 (1). The four cystein side chains labeled in red 
are chelating the zinc atom (grey). Sequence alignment of ZNF265 and the TET family proteins was done with 
ClustalW. Both structures were visualized with the program PYMOL.
?? α1 ?? ?? α2 ??
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well as the structure of the EWS zinc finger is not solved so far, but the high sequence
similarity to the ZNF256 zinc finger, whose structure was solved by NMR (1), allows
homology modeling to get the structure of the EWS zinc finger (Fig 1.5 B), as it was done for 
TLS/FUS (85). For ubiquitin-binding of the Npl4 zinc finger, a Thr-Phe dipeptide between the 
two cysteins is needed. In case of EWS and TLS/FUS, this dipeptide is replaced by Glu-Asn, 
so the EWS zinc finger might rather functions in RNA-interaction than contributing to 
ubiquitin-binding
Arginine-glycine rich regions (RGG boxes)
The two structured domains of the EWS RBD (RRM and ZF) are surrounded by arginine-
glycine rich domains (RGG boxes 1-3). Such RGG boxes are found in many RNA-binding 
proteins like heterogeneous nuclear ribonucleoproteins, nucleolin, fibrillarin, or the EWS 
homologues TLS/FUS and TAFII68. These RGG- or RGR-repeats are the preferred substrates 
for protein arginine methylation, and in the EWS protein all 30 arginines within the RGG 
boxes were found to be dimethylated in vivo (57). The functional role of the EWS protein 
RGG boxes and their methylation is still unknown. RGG- boxes, unmethylated or methylated,
do not possess any stable secondary or ternary structure and seem to be flexible linker 
between structured domains (85). The RGG rich region of the fragile X mental retardation
protein (FMRP) specifically binds mRNA (87). Because recombinant produced peptides, 
which can not be methylated in bacteria, were used in this study, the role of FMRP-
methylation in mRNA-binding needs to be investigated.
Nuclear localization sequence (NLS)
The last 17 C-terminal amino acids (639-656) of the EWS protein form a new nuclear 
localization sequence. The functional key amino acids within the NLS are Arg 648, Arg 652, 
Pro 655, and Tyr 656, as the mutation of each of these residues to Ala prevents the nuclear 
import of the EWS protein (79). The so called PY-NLS, also present in hnRNP A1, was found 
???????? ???????????????2 (Transportin) and currently, further 81 proteins were predicted to 
contain such a PY-NLS (80).
Subcellular localization of the EWS protein
The EWS protein was identified by immunostaining and overexpression as a GFP-fusion 
protein to localize mainly in the nucleus of several cell lines (79). Differential centrifugation 
and surface labeling of cells revealed that subpopulations of the EWS protein are also located 
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in the cytoplasm and attached to the cell membrane (57,45). Other nuclear proteins like 
nucleolin and hnRNP K are known to locate additionally at the cell surface and a receptor 
function of these proteins was proposed (88,89). However, receptor activity or specific 
ligands of the surface-exposed EWS protein are not known so far.
Post-translational modifications of the EWS protein
The EWS protein is heavily post-translationally modified. All 30 arginines within the RGG 
boxes were found to be asymmetrically dimethylated, independent on the isolation of the 
EWS protein from the nuclear or cell-membrane fraction (57). By now, no unmethylated 
EWS protein was isolated from cells. Arginine methylation can affect subcellular localization 
as demonstrated for hnRNP A2 (28) and hnRNP Q (29) and a similar function was proposed 
for the EWS protein. Recently, we could show in our lab, that the subcellular localization of 
the EWS protein is not affected by this modification (79). Inhibition of the methyltransferases 
in the cell results in a decreased expression level of the EWS protein (45).
Additionally to the arginine methylation, the EWS protein is supposed to be phosphorylated. 
The Ser266 was shown to be phosphorylated by protein kinase C, which prevents calmodulin 
binding to the IQ domain (78) and regulates the transcriptional activity of the fusion proteins 
EWS/Fli1 and EWS/Atf1 (90). Several Ser and Tyr residues of the EAD are predicted to be 
phosphorylated, however, an experimental confirmation is still missing. It is known, that 
especially disordered regions are the target for numerous post-translational modifications as it 
was shown e.g. for p53 (91,92), c-Src kinase (93), or the unstructured N-terminal tail of 
histones, whose phosphorylation, acetylation, and methylation is crucial for the histone 
functions (94). Consistent with that, only the disordered parts of the EWS protein are 
modified, whereas the structured RRM and ZF domains harbor no PTMs.
Cellular functions of the EWS protein
Transcriptional co-activation
The N-terminal EAD in oncogenic EWS fusion proteins function as potent transcriptional 
activator. Although the transforming potential is repressed in the wild-type EWS, it still acts 
as a transcriptional (co)-activator. The EWS protein associates with integral components of 
the transcriptional pre-initiation complex like the C-terminal domain of the RNA polymerase 
II, and the TFIID complex (95). A direct function as co-transcriptional activator was shown 
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by the interaction of the EWS protein with the transcriptional activators CBP/p300 and their 
co-activation in a cell line- and promoter-specific manner (96). The EWS protein also 
interacts with Brn-3a, a POU-family transcription factor involved in the regulation of genes 
that control neural development. Additionally, the transcription of a Brn-3a isoform is 
activated by the EWS protein (97). Oct-4, a transcription factor which also belongs to the 
POU family, is expressed in embryonic stem cells and activates genes involved in maintaining 
an undifferentiated totipotent state by preventing differentiation. The EWS protein was found 
to interact with the POU domain of Oct-4 and to increase its transcriptional activity (98).
As already mentioned the wild type EWS protein (co)-activates different genes and 
transcription factors than the chimeric EWS fusion proteins. Alex et al (2005) could show, 
that multiple RGG boxes of the C-terminal RBD of the EWS protein, which are absent in the 
fusion proteins, can repress the transcriptional activity of EWS fusion proteins. Also other 
well known activation domains like CREB or VP16 were repressed when fused to the RGG 
boxes, but the presence of more than one activation domains diminished the repression (76). 
The C-terminal RBD of the EWS protein including the RGG boxes therefore plays an 
important role in the regulation of its N-terminal activation domain. Interestingly, the 
replacement of the arginine residues by lysines did not alter the EAD repression (76), so the
basic charge and not the methylation of the arginines seem to be important for repression.
Splicing
A role of the EWS protein in splicing was proposed due to its interaction with several 
splicing factors. By yeast-two hybrid screens it was found, that the EAD of the EWS protein 
interact with the splicing factors U1C (99) and ZFM1 (100). The RBD can also interact with 
Ser/Arg-rich splicing factors TASR-1 and TASR-2 (101,102) and with the splicing factor YB-
1 (103). The EWS protein co-purifies with the heterogeneous nuclear ribonucleoproteins 
(hnRNP) A1 and C1/C2 (104) and in a large scale proteomics chacacterization of the human 
spliceosome, more than 300 different components of this huge and highly dynamic protein 
complex were identified, among them the EWS protein (105). The contribution of the EWS 
protein in pre-mRNA processing and splicing, however, is still unknown.
mRNA transport and translation
Splicing and m-RNA export out of the nucleus are highly related processes. Many RNA-
binding proteins, like hnRNP A1 were found to bind already to the pre-mRNA and remain 
bound until the spliced mRNA product is exported to the cytoplasm and translation is initiated. 
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Other proteins like poly(A)-binding protein (PABP)-2 dissociate in the nucleus from the 
protein-RNA complex, whereas new binding partners like PABP-1 are recruited in the cytosol. 
Usually, the EWS protein is located in the nucleus and is not supposed to frequently shuttle 
between nucleus and cytosol. Nevertheless, the EWS protein might contribute in the transport 
of spliced mRNA, as it was identified in RNA-transporting granules in neurons, which move 
along the microtubules mediated by kinesin (106). Angenstein et al. investigated the protein 
composition of messenger ribonucleoprotein (mRNP) complexes bound either to non-
translated or to translated poly(A)-mRNA. The EWS protein was identified only in the non-
translated fraction and not in the polysome-bound mRNPs indicating, that it does not play a 
direct role in translation (107).
DNA-recombination, -pairing, and -repair
The three TET-family proteins TLS/FUS, EWS, and TAFII68 have DNA-pairing activity as 
it was shown by Guipaud et al. (108). Consistent with these results, TLS-deficient mice fail to 
develop B-lymphocytes, a process which is characterized by a couple of gene rearrangements. 
Recently, Li et al. succeeded to produce also EWS null mutant mice, which show a very high 
percentage of mortality (90%). Similarly, the few surviving EWS -/- mice fail to develop
intact B-lymphocytes. Whereas the lack of TLS results in B-cells with dysfunction in the 
primary antibody production (109), the EWS -/- mutants have a defect in pre-B-lymphocyte 
development during pro- to pre-B cell transition (110). The deletion of the EWS gene affects 
also meiosis, as the formation of bivalent XY chromosomes is drastically reduced (110). This 
defect in formation of bivalent chromosomes during meiosis was also observed in TLS -/-
mutants, however, there the pairing of the autosomal chromosomes was affected (111).
Finally, EWS-deficient cells are highly sensitive to radiation, implying also a function in 
DNA repair (110).
Signal transduction
A role in signal transduction was proposed, as the EWS protein interacts with calmodulin 
via its IQ domain. This interaction can be repressed by phosphorylation of Ser266 by protein 
kinase C (PKC) (78). Also the SH3 domain of Brutons kinase (112) and Tyrosine kinase Pyk2 
were found to interact with the EWS protein, the latter one is supposed to function in G-
coupled receptor signaling (113). 
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In summary, the EWS protein is an intrinsic disordered protein with only two structured 
domains (RRM and ZF). It is extensively methylated at arginine residues and supposed to be 
phosphorylated manifold. Beside the cancer-associated transactivation activity of the fusion 
protein, the wild-type EWS protein participates in several cellular processes like 
transcriptional control, splicing and mRNA processing, DNA-pairing and –repair, and signal 
transduction. Such multi-functionality is characteristic for intrinsic disordered proteins, as the 
disordered domains enable a high binding diversity by interaction with numerous binding 
partners with high specificity and low affinity. However, the role of methylation and 
phosphorylation in all these processes the EWS protein is involved in has not been addressed.
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2. Aim of the Thesis
Previous studies in our lab have revealed that the human RNA-binding protein EWS 
contains 30 dimethylated arginine residues situated in arginine-glycine rich regions (RGG 
boxes) within the RNA-binding domain (RBD). One goal of this study was to identify the 
protein arginine methyltransferases (PRMTs), which catalyze the post-translational 
methylation of the EWS protein. To date, nine human PRMTs have been described, which 
differ in substrate specificity and subcellular localization (nuclear, cytoplasmic, or cell 
membrane-associated). In vitro methylation experiments using recombinant EWS protein and 
selected recombinant PRMTs yield not only information about the enzyme that methylates the 
EWS protein but also first clues, where in the cell the methylation of the EWS protein takes 
place. The usual way of analyzing arginine methylation is the detection of incorporated 
radiolabeled methyl groups. In this study, mass spectrometry was chosen as main method of 
analysis. In comparison to radiolabeling, mass spectrometry yields not only the total amount 
of incorporated methyl groups, but also identifies the methylation sites, which is important for 
investigating sequence specificities of the different PRMTs.
The EWS gene undergoes tumor-related chromosomal translocations in the Ewing sarcoma 
family of tumors. The resulting oncogenic fusion proteins of the N-terminal EWS activation 
domain and C-terminal DNA-binding domains of ETS transcription factors have been 
investigated in detail. However, the function of the full-length proto-oncoprotein EWS in 
tumor suppression or in other conceivable cellular processes is largely unknown as the role of 
the extensively methylated RNA-binding domain of the EWS protein. To outline the spheres 
of action of the EWS protein, EWS-interacting proteins should be identified in the second part 
of this study. Large amounts of methylated and unmethylated EWS protein were a 
prerequisite for experiments on the co-purification, co-precipitation, and co-localization of 
potential EWS-binding proteins. As the yield of purified wild-type EWS protein from 
eukaryotic cell lines is rather poor, recombinant full-length EWS protein as well as diverse 
deletion mutants, all in unmethylated and methylated form, have been made available (in 
collaboration with Rouzanna Zakaryan). From the identification of the co-purified proteins by 
mass spectrometry, insights into the cellular roles of the multifunctional EWS protein and its 
post-translational modifications may be expected.
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3. Different Methylation Characteristics of Protein Arginine Methyl-
transferase 1 and 3 towards the Ewing Sarcoma Protein and a peptide
Steffen Pahlich, Karim Bschir, Claudio Chiavi, Larisa Belyanskaya, and Heinz Gehring
Proteins. 2005 Oct 1;61(1):164-75.
Summary
The multifunctional Ewing Sarcoma (EWS) protein, a member of a large family of RNA-
binding proteins, is extensively asymmetrically dimethylated at arginine residues within RGG 
consensus sequences. Using recombinant proteins we examined whether type I protein 
arginine methyltransferase (PRMT)1 or 3 is responsible for asymmetric dimethylations of the 
EWS protein.
After in vitro methylation of the EWS protein by GST-PRMT1, we identified 27 
dimethylated arginine residues out of 30 potential methylation sites by mass spectrometry-
based techniques (MALDI-TOF MS and MS/MS). Thus, PRMT1 recognizes most if not all 
methylation sites of the EWS protein. With GST-PRMT3, however, only 9 dimethylated 
arginines, located mainly in the C-terminal region of EWS protein, could be assigned, 
indicating that structural determinants prevent complete methylation. In contrary to previous 
reports this study also revealed that trypsin is able to cleave after methylated arginines. Pull-
down experiments showed that endogenous EWS protein binds efficiently to GST-PRMT1 
but less to GST-PRMT3, which is in accordance to the in vitro methylation results. 
Furthermore, methylation of a peptide containing different methylation sites revealed 
differences in the site selectivity as well as in the kinetic properties of GST-PRMT1 and GST-
PRMT3. Kinetic differences due to an inhibition effect of the methylation inhibitor S-
adenosyl-L-homocysteine could be excluded by determining the corresponding Ki values of 
the two enzymes and the Kd values for the methyl donor S-adenosyl-L-methionine.
The study demonstrates the strength of MS-based methods for a qualitative and quantitative 
analysis of enzymic arginine methylation, a posttranslational modification that becomes more 
and more the object of investigations.
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Introduction
Methylation of arginine residues is catalyzed by protein arginine N-methyltransferases 
(PRMT), which use S-adenosyl-L-methionine (AdoMet) as donor of methyl groups 1. Several 
cellular processes like subcellular localization of proteins, signal transduction, transcriptional 
regulation, and also the ability of proteins to bind to nucleic acids are affected by arginine 
methylation 2-7.
The type I PRMT catalyze the formation of NG-monomethylarginine and asymmetric ω-
NG,N’G-dimethylarginine, while type II enzymes form NG-monomethylarginine and 
symmetric ω-NG,N’G-dimethylarginine 8. Type I enzymes include the yeast methyltransferase 
Rmt1 9, human PRMT1 10, PRMT3 11, coactivator-associated arginine methyltransferase 
(CARM1)/PRMT4 12, and PRMT6 13. Several in vivo substrates for type I PRMT have been 
identified, among them fibrillarin, nucleolin, heterogeneous nuclear ribonucleoproteins 
(hnRNP), basic fibroblast growth factor, and histones 8. PRMT5/JBP1 and PRMT7 are the 
only type II methyltransferases identified so far 14,15. Substrates for symmetric arginine 
methylation known today are myelin basic proteins and Sm ribonucleoproteins 15-17.
The homologous type I arginine methyltransferases PRMT1 and PRMT3 used in this study 
differ not only in the N-terminal domain, where PRMT3 has a putative C2H2 type zinc-finger 
motif and a tyrosine phosphorylation consensus sequence, but also in substrate specificity, 
oligomerization, and subcellular localization 11. Whereas PRMT1 is the main arginine 
methyltransferase in eukaryotic cells 18 with a wide substrate spectrum, only one 
physiological substrate of PRMT3, the 40S ribosomal protein S2, was identified so far 19. 
Although PRMT1 and PRMT3 differ in their substrate specificity, they both dimethylated 
arginine residues within an RGG consensus sequence 11.
In cellular Ewing sarcoma (EWS) protein asymmetric dimethylation of arginines within 
such RGG domains was found 20. This protein therefore is a potential substrate for the 
methyltransferases PRMT1 and PRMT3. The EWS protein consists of two main large 
domains, the N-terminal transcriptional activation domain (EAD) and the C-terminal RNA-
binding domain (RBD). The EAD is involved in Ewing family tumors where chromosomal 
translocations lead to the formation of chimeric fusion products with oncogenic potential 
between the EAD coding region of the EWS gene and different ETS (erythroblastosis virus-
transforming sequence) transcription factors 21-23. However, only the N-terminal part of the 
EWS gene is involved in the translocation, and loss of RBD increases activation of EAD 24,25.
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The function of native EWS protein remains unclear. The C-terminal RBD contains three 
arginine-glycine rich domains (RGG boxes), an RNA-recognition motif, and a C2C2 type zinc 
finger motif (see Fig. 3.4 C). It belongs to a large family of RNA-binding proteins such as 
hnRNP, mRNA poly(A)-binding proteins, and alternative splicing factors 26-29. Although 
EWS protein is supposed to be a nuclear protein, it is also present in the cytosol and on the 
cell surface 20. Independent on its localization, EWS protein isolated from cells is extensively 
dimethylated on arginine residues in the C-terminal RBD. Out of 30 arginines within possible 
methylation sites, 29 arginines were found to be asymmetrically dimethylated 20. Recent 
studies indicated, that expression of EWS protein in the various subcellular compartments is 
affected by the methylation process, in particular on the availability of intracellular AdoMet 30. 
However, the functional relevance of the extensive arginine methylation of the EWS protein 
as well as the methyltransferases, which are catalyzing the methylation of EWS protein are 
still unknown.
In this study, we demonstrate that the type I methyltransferases GST-PRMT1 and GST-
PRMT3 have different methylation characteristics towards a synthetic peptide containing four 
RGG-methylation sites. In vitro methylation of the recombinant GST-EWS protein with GST-
PRMT1 and GST-PRMT3 as well as pull-down experiments with cell extracts show that EWS 
protein interacts with both PRMT1 and PRMT3 but in a different manner. This underlines the 
differential substrate specificity of the two methyltransferases. MALDI-TOF MS and MS-
based peptide sequencing (MS/MS) was used to monitor and identify specific arginine 
methylations.
Materials and Methods
Materials - The cDNA of EWS was a generous gift from Dr. Olivier Delattre (Institut Curie, 
Pathologie Moléculaire des Cancers, Paris Cedex). pGEX(SN)-PRMT1 and pGEX(SN)-
PRMT3 constructs were kindly provided by Dr. Harvey R. Herschman (UCLA, Molecular 
Biology Institute, Los Angeles). E.coli lysate containing GST-PRMT6 was kindly obtained 
from Dr. Michael Hottiger (Institut für Veterinärbiochemie und Molekularbiologie, 
Universität Zürich).
Preparation, Expression and Purification of GST Fusion Proteins - The EWS cDNA 23
was PCR-amplified using primers 5’ATCTGGAATTCAAATGGCGTCCACGGATTACA-
GTACCTATAGCCAAGCTGCAGC3’ and 5’CTGGTAGTCAATGCAGCTCGAGGGGGT-
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CTCTGCATCTAGTAGG3’. The resulting fragment was digested with EcoRI and XhoI and 
inserted into the GST fusion vector pGEX-6P-2 (Amersham Pharmacia Biotech). The GST 
fusion proteins were expressed and purified according to the manufacturer`s protocol 
(Amersham Pharmacia Biotech) using XL1-Blue competent cells (Stratagene) for GST-EWS 
and BL21 (DE3) competent cells (Novagen) for GST-PRMT1 and GST-PRMT3. The 
purification of each protein was checked by SDS-PAGE as shown for GST-EWS protein (Fig 
3.3, inlet, molecular mass markers (kDa) are indicated). Both bands represent full-length 
GST-EWS protein, as determined by MS analysis. The reasons for differences in the 
electrophoretic mobility, however, are unclear. Purified proteins were stored at –80°C in 50 
mM sodium phosphate, pH 7.4. The protein concentration was determined by UV-
spectrometry, using the theoretically calculated ?280 (ExPASy), or by BioRad assay. 
Activity Determination of GST-PRMT1 and GST-PRMT3 - To determine and compare the 
specific activities of GST-PRMT1 and GST-PRMT3, a synthetic peptide corresponding to 
residues 676–692 of human nucleolin (GRGGFGGRGGFRGGRGG-NH2, ANAWA 
Biomedical Services & Products) was used as substrate in methylation assays. The peptide 
was incubated with GST-PRMT1 or GST-PRMT3 and AdoMet (Amersham) in a final 
volume of 50 ?l in 10 mM sodium phosphate, pH 7.4 for various periods at 30°C 
(concentrations are denoted in the figure legends). The methylation reaction was stopped by 
addition of an equal volume of 50% (v/v) acetonitrile (ACN) / 0.1% (v/v) trifluoracetic acid 
(TFA). Chymotryptic digestion of the peptide was performed in 10 mM sodium phosphate, 
pH 7.9 with a final concentration of 1 ?g chymotrypsin / ml for 15 min at 30°C. 
Quantification of Methylation - Arginine methylation does not affect the net charge of the 
peptide. To test whether the ionisation efficiency of the methylated and non-methylated 
reference peptide during MALDI-TOF MS is the same, unmethylated and eight times 
methylated peptide was mixed in varying ratios. The measured ratios of the monoisotopic 
peak intensities in the MALDI-TOF spectrum correspond to the theoretic ratios. Therefore, 
peptide methylation can be quantified. The sum of monoisotopic peak intensities 
(unmethylated and methylated) in a spectrum was set equal to the starting peptide 
concentration. From the peak intensities in a spectrum the fraction of each methylation 
intermediate of the starting concentration was estimated. To calculate the total amount of 
incorporated methyl groups at a certain time point, the concentrations of all methylation 
intermediates at that time point were multiplied by their methylation state and added up.
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Kinetic calculations - Kinetic values were calculated using hyperbolic curve fitting 
(SigmaPlot 8.0) of the measured values to the Michaelis-Menten equation. Competitive 
inhibition of GST-PRMT1 and GST-PRMT3 by AdoHcy was determined by measuring the 
initial rates of peptide methylation with GST-PRMT1 or GST-PRMT3 in the presence of 
AdoMet and varying concentrations of AdoHcy indicated in figure 3.1 E. The Ki values were 
calculated using the equation
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where the apparent Ki’ corresponds to the inhibitor concentration at 50% inhibition (Fig. 3.1
E). Ki is the inhibition constant, [S] denotes the concentration of AdoMet and Kd the 
dissociation constant of AdoMet. Kd values of GST-PRMT1 and GST-PRMT3 for AdoMet 
were determined by measuring the decrease of tryptophan fluorescence at varying 
concentrations of AdoMet. Excitation was set at 285 nm and emission spectra from 295 to 
420 nm were recorded. The fluorescence change at λmax (343 nm) was plotted against the 
concentration of AdoMet and the Kd values were estimated by hyperbolic curve fitting.
Methylation of Recombinant GST-EWS Protein - GST-EWS was incubated with GST-
PRMT1 or GST-PRMT3 and AdoMet in a final volume of 50 ?l 10 mM sodium phosphate, 
pH 7.4 for 3 h at 30 °C (concentrations are denoted in the figure legends). Addition of 10 ?l of 
two fold Laemmli sample buffer to 10 ?l of the reaction mixture and heating for 5 min at 
95°C terminated the reaction.
In-gel Digestion and Mass Spectrometry - Gel pieces containing the coomassie-stained 
protein band of GST-EWS were excised, destained twice in 100 ?l 40% ACN / 0.1% TFA in 
100 mM ammoniumbicarbonate for 15 min, washed in 100 ?l water for 15 min, dehydrated in 
100% ACN for 5 min and dried completely. In-gel digestion was carried out with trypsin 
(Promega, 6 ?g/ml) or chymotrypsin (Promega, 5 ?g/ml) overnight at room temperature in 15 
?l 0.5 mM Tris-HCl, pH 8.0. One ?l of the digest was mixed with 3 ?l of matrix solution (?α-
cyano-4-hydroxycinnamic acid (α-CCA) saturated in 40% ACN / 0.1% TFA) and spotted 
directly onto a MALDI target. MALDI-TOF MS was performed at the Protein Analysis Unit 
(Universität Zürich) on a Bruker Biflex instrument in the reflector mode employing pulsed ion 
extraction. The spectra were mass calibrated externally. To assign and identify methylated 
peptides, spectra of native EWS protein 20 but also theoretic calculated digests of EWS protein 
(PeptideMass from ExPASy) were used as reference. The methylated peptides were assigned 
Arginine Methylation of the EWS protein 43
according to differences (addition of 14 Da per methylation) observed in spectra of PRMT 
treated and untreated EWS protein. 
Reverse-Phase HPLC and MALDI-TOF MS/MS - RP-HPLC was performed at the 
Functional Genomics Center Zurich (FGCZ) on an LC-Packings system as described 
elsewhere 31 with some modifications. The sample was desalted using C18 ZipTips (Millipore, 
Bedford, MA), peptides were eluted in 10 ?l of 50% ACN / 0.1% TFA, dried completely and 
resolved in 10 ?l of solvent A (1% ACN / 0.1% TFA). The sample was loaded directly to the 
system and peptides were separated with a flow rate of 0.3 ?l/min using the following 
gradient: 0-5 min, 0% solvent B (80% ACN / 0.1% TFA); 5-35 min, 0-50% B; 35-40 min, 50-
100% B, followed by 100% B. The HPLC eluent was mixed with MALDI matrix (3 mg α-
CCA in 70% ACN / 0.1% TFA) at a flow rate of 1 ?l/min before being spotted every 20 s on 
a blank MALDI plate (Applied Biosystems). LC-samples, spotted on a MALDI target, were 
analyzed at the FGCZ on a 4700 Proteomics Analyzer MALDI-TOF/TOF (Applied 
Biosystems) as described 31 using 1500 shots per MS spectrum and 3000-6000 shots per 
MS/MS spectrum. Maximal 10 MS/MS spectra were recorded per sample spot from precursor 
ions with a minimal signal-to-noise (S/N) ratio of 40 in the mass spectrum. GPS Explorer 
(Applied Biosystems) was used for submitting the data acquired from TOF/TOF for database 
searching using Mascot (www.matrixscience.com). The peptide tolerance was set to 75 ppm 
and the MS/MS tolerance to 0.2 Da.
GST Pull-down Experiments - Purified GST-PRMT1 or GST-PRMT3 (10 ?g each) was 
incubated for 1 h at 4°C with 30 ?l of glutathione-agarose (Sigma). Cell extracts from Jurkat 
Cells and H9 cells were fractionated as described before 30. Nuclear cell extracts (150 ?g 
protein in 450 ?l EBC buffer: 50mM Tris-HCl, 120 mM sodium chloride, 0.5% (v/v) Nonidet 
P-40, 1mM 1,4-Dithio-DL-threitol, pH 8.0) were incubated for 1 h at 4°C with agarose-bound 
GST-PRMT1, GST-PRMT3, or GST alone. The agarose was washed three times with EBC 
buffer and bound proteins were extracted by incubation with two fold Laemmli sample buffer 
for 5 min at 95°C.
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Figure 3.1: Time course of methylation of the peptide by GST-PRMT1 (A) and GST-PRMT3 (B). 
Peptide (1 ?M) was incubated with 0.1 ?M of each enzyme and AdoMet (100 ?M) and analyzed by 
MALDI-TOF MS at the indicated time points. The theoretical m/z value of the peptide is 1563.72 
(unmethylated) or 1675.93 (completely methylated). All other peaks correspond to methylation 
intermediates (+14 per incorporated methyl group) and the numbers indicate the amount of 
incorporated methyl groups. (C): Kinetics of incorporation of the eight methyl groups per peptide by 
GST-PRMT1 (?) or GST-PRMT3 (?). (D): Dependence of the initial rates of peptide methylation with 
0.1 ?M GST-PRMT1 (?) or 0.1 ?M GST-PRMT3 (?? on the concentration of the peptide. (E): 
Inhibition of methyltransferase activity by AdoHcy. Methylation was performed with 0.1 ?M GST-
PRMT1 (?) or 0.1 ?M GST-PRMT 3 (?), 1 ?M peptide, and 10 ?M AdoMet in the absence and 
presence of AdoHcy. Initial velocities at different concentrations of AdoHcy were measured and the 
relative activities are indicated.
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Results
Comparison of Activities of GST-PRMT1 and GST-PRMT3 
in Peptide Methylation
To prove and compare the activities of GST-PRMT1 and GST-PRMT3, a synthetic peptide 
(GRGGFGGRGGFRGGRGG-NH2) containing four unmethylated arginine residues within an 
RGG sequence was used as substrate for in vitro methylation (Materials and Methods). The 
methylation of the peptide by GST-PRMT1 and GST-PRMT3 was monitored at different time 
points by MALDI-TOF MS. Both enzymes showed activity towards the peptide but with 
distinct differences in the pattern of methylation during the time course of the reaction.
The incorporation of methyl groups at all four arginines by GST-PRMT1 proceeded linearly 
until the peptide was methylated almost completely (Fig. 3.1 A and C). By plotting initial 
rates of methylation of the unmethylated peptide at different peptide concentrations (Fig. 3.1
D) kinetic constants were calculated resulting in a kcat/Km value of 8.1*10
-3
?M-1s-1 (Table I, 
for calculations see Materials and Methods). Peptide methylation with GST-PRMT3 was 
initially faster than with GST-PRMT1 (Fig. 3.1 B and C), already after 15 minutes, all eight 
methylation intermediates could be observed. After an initial linear phase, the rate decreased 
steadily until complete methylation of the peptide was attained after ~7 hours. The initial rates 
of peptide methylation by GST-PRMT3 at different substrate concentrations yielded a kcat/Km
value of 0.1 ?M-1s-1 which is ~12 times higher than the value of GST-PRMT1 (Fig. 3.1 D; 
Table I).
The origin of the different peptide methylation characteristics could be due to a differential 
inhibition effect of S-adenosyl-L-homocysteine (AdoHcy), the product of the methyl donor 
AdoMet. AdoHcy is known to be a competitive inhibitor of arginine methyltransferases 1. In a 
cellular environment, hydrolysis of AdoHcy to adenosine and homocysteine by AdoHcy-
hydrolase, which was not present in the in vitro methylation reactions, prevents accumulation 
of AdoHcy.
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In order to determine whether inhibition by AdoHcy arising from the peptide methylation 
influences the activity of the PRMT, peptide methylation was performed in the absence and 
presence of varying concentrations of AdoHcy (Fig. 3.1 E). Increasing amounts of AdoHcy 
inhibited the methylation activity of both GST-PRMT1 and GST-PRMT3 under the present 
conditions with an apparent Ki’ of 8.6 µM and 9.7 ?M, respectively. For calculating the 
competitive inhibition constant Ki, the Kd values of the PRMT for AdoMet were determined 
by measuring the quenching of tryptophan fluorescence of PRMT on addition of AdoMet 
(Materials and Methods). The Kd values of GST-PRMT1 and GST-PRMT3 for AdoMet and 
the calculated competitive inhibition constants Ki (Table I) indicated similar affinities of each 
methyltransferase for the substrate AdoMet and for the product AdoHcy. Under the conditions 
used in Fig. 3.1 A-C (100 ?M AdoMet), the initial rates of peptide methylation are hardly 
influenced by the formation of AdoHcy. Even after complete methylation of 1 ?M of peptide, 
AdoMet remains in a great excess compared to AdoHcy resulting in a negligible inhibition.
Thus, other reasons must be responsible for the decline of methylation rate in the case of 
GST-PRMT3. Three of the four arginines of the peptide are embedded in a GRGG sequence 
motif whereas one arginine has a phenylalanine at its N-terminal site (FRGG). In order to 
investigate whether GST-PRMT3 has any sequence preferences or whether the arginine 
residues of the peptide are methylated randomly, the methylation reaction was stopped before 
completion (Fig. 3.2 A, left). At that time point, mainly six-, seven-, and eight-fold 
methylated peptide was found. Chymotryptic digestion of the peptide yielded the peptide 
fragments 1-11 and 12-17 with masses of 1024.5 Da and 558.7 Da, respectively, in the 
unmethylated state. Only a four-fold methylated state could be observed in fragment 1-11, 
whereas fragment 12-17 is present 
with three peaks representing the two-, 
three-, and four-fold methylated state 
(Fig. 3.2 A, right). Obviously, 
arginines 2 and 8 were both 
dimethylated at that time point, 
whereas one of the arginines 12 and 
15 was dimethylated and one was 
present in the un-, mono-, and 
dimethylated state. Most likely it is 
Arg 12 (FRGG) that differs in 
TABLE I. Kinetic properties of GST-PRMT1 and 
GST-PRMT3 towards the peptide, AdoMet, and 
AdoHcy.
GST-PRMT1 GST-PRMT3
Vmax 0.04 µM / min 0.22 µM / min
Km 0.8 µM 0.35 µM
kcat 6.5 * 10
-3 s-1 3.6 * 10-2 s-1
kcat / Km 8.1 * 10-3 µM-1s-1 0.1 µM-1s-1
Kd (AdoMet) 1.1 µM 3.9 µM
Ki (AdoHcy) 0.8 µM 2.7 µM
Values were calculated as described (Materials and 
Methods) using hyperbolic curve fitting of Fig. 3.1 D-E.
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sequence from the others. Thus, arginines within a GRGG sequence (Arg 2, 8, and 15) motif 
are probably methylated faster by GST-PRMT3 than those in a FRGG (Arg 12) motif. The 
same experiment was performed with GST-PRMT1 (Fig. 3.2 B). The mass spectrum of the 
chymotryptic fragments of incomplete methylated peptide (Fig. 3.2 B, right) showed in both 
fragments the same methylation distribution of two, three, and four methyl groups per peptide 
fragment, indicating that GST-PRMT1 methylates in a random order without sequence 
preference.
Methylation of GST-EWS Protein
Given the activity of GST-PRMT1 and GST-PRMT3 towards the reference peptide, we 
investigated whether GST-EWS protein, which is extensively methylated in vivo 20, is a 
substrate for the two methyltransferases. Recombinant GST-EWS protein was incubated with 
GST-PRMT1 in the presence of AdoMet, the reaction was stopped after 3 h and GST-EWS 
protein was separated from GST-PRMT1 by SDS-PAGE. The band representing the full-
Figure 3.2: Analysis of sequential methylation of the peptide. Methylation of the peptide with GST-
PRMT3 (A) or GST-PRMT1 (B) was stopped before completion and analyzed with MALDI-TOF MS 
(left). The peptide was cleaved with chymotrypsin and the resulting fragments (1-11; 12-17) were 
subjected to MS analysis to estimate their methylation state (right). The numbers indicate the 
incorporated methyl groups. The peak at m/z 568 labeled with an asterisk is a signal arising from the 
matrix (α-CCA).
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Figure 3.3: MALDI-TOF mass spectra of in vitro methylated GST-EWS by GST-PRMT1. GST-EWS 
(2 ?M) was incubated with GST-PRMT1 (1 ?M) and AdoMet (1 mM) for 3 h at 30°C and subjected to 
SDS-PAGE. The dominant band after Coomassie blue staining representing the full-length GST-EWS 
protein (inlet) was cut out and in-gel digested with chymotrypsin. (A) MALDI-TOF mass spectrum of 
unmodified GST-EWS protein. Peaks labeled with an arrow could be assigned to GST-EWS protein; 
peaks additionally labeled with an asterisk are EWS peptides containing RGG consensus sequences. (B)
MALDI-TOF mass spectrum of GST-EWS protein methylated by GST-PRMT1. Peaks with a mass 
shift corresponding to the addition of methyl groups are indicated with an asterisk. (C) Enlarged spectra 
of A and B.
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length GST-EWS protein was cut out and subjected to tryptic or chymotryptic in-gel 
digestion. The resulting peptides were analyzed by MALDI-TOF MS as described 20. In the 
MALDI spectrum of untreated GST-EWS protein, all dominant peaks could be assigned to 
the GST-EWS protein (Fig. 3.3 A). In the mass fingerprint of GST-EWS protein treated with 
GST-PRMT1 several mass shifts could be observed (Fig. 3.3 B). Dominant peaks of the 
untreated GST-EWS protein decreased after GST-PRMT1 treatment and new peaks 
corresponding to the addition of methyl groups appeared (Fig. 3.3 C). 
Figure 3.4: Sequence coverage by identified peptides of the EWS protein methylated either with 
GST-PRMT1 (A) or GST-PRMT3 (B) for 3 hours. The shaded regions represent tryptic peptides, 
chymotryptic peptides are labeled with a box. Monometylated arginines are bold (R), arginines found 
to be dimethylated are bold and underlined (R). Identified unmodified methylation sites are labeled 
with an asterisk («). (C): Domains of the EWS protein and the corresponding numbers of amino acid 
residues. EAD – EWS activation domain; RGG1-3 – arginine-glycine rich domains 1-3; RRM – RNA 
recognition motif; ZF – putative zinc finger domain.
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Chymotryptic digestion is not as specific as tryptic digestion, resulting in a larger number of 
possible EWS fragments. Additional modifications like methionine oxidation (mass increase 
of 16 Da), arginine monomethylation (+14 Da), or dimethylation (+28 Da) even increase the 
number of theoretically generated peptides, among them several peptides with identical 
masses. To confirm the identity of the matched tryptic and chymotryptic peptides, the digests 
were subjected to RP-HPLC followed by MALDI-TOF MS/MS sequencing of the peptides
(see Materials and Methods). Taken together, the analyzed tryptic and chymotryptic peptides 
covered a large part of the EWS sequence (Fig. 3.4 A), and 27 dimethylated arginines were 
found and confirmed by MS/MS analysis after GST-PRMT1 treatment (Table II). In MS/MS 
spectra, as exemplified on the chymptryptic peptide 576 – 588 including a dimethylated 
arginine, all dominant peaks could be assigned as b- or y-fragment ions or internal fragments 
(Fig. 3.5). The appearance of specific fragment ions resulting from the loss of 
dimethylammonium (m/z 46) and the release of dimethylammonium from the precursor ion 
([M+H]+-45) confirmed the asymmetric dimethylation of arginine residues 32,33. Arginines 
464 and 563 were found to be unmodified and arginine 490 was not covered by the identified 
peptides (Fig. 3.4). Some peptides were present in different methylation states (e.g. 
chymotryptic peptide 589-599) indicating, that the methylation reaction was not complete 
after 3 h. Nevertheless, almost all methylation sites were recognized by GST-PRMT1.
Although GST-PRMT3 has a higher activity than GST-PRMT1 towards the reference 
peptide, no methylation activity towards the EWS protein was found when comparable 
activity units of GST-PRMT3 were used as it was done with GST-PRMT1. After treatment of 
the GST-EWS protein (2 µM) with 1 ?M of GST-PRMT3, mass shifts could be observed as 
well, but much fewer dimethylated arginines were found. Again, a large part of the EWS 
sequence was covered by the identified tryptic and chymotryptic peptides (Fig. 3.4 B), but 
only nine dimethylated and three monomethylated arginines were found by MS/MS (Table 
Figure 3.5: MS/MS spectrum of the chymotryptic 
peptide 576 – 588 (m/z 1279.6) of the EWS protein 
methylated with PRMT1. The labeled y- and b-
fragment ions as well as the internal fragments 
cover the sequence including the dimethylated 
arginine (dmR) 581. Ions at m/z 46 and at m/z 
1234.6 ([M+H]+-45) resulting from the loss of 
dimethylammonium are additional proofs for the 
asymmetric dimethylation of the arginine residue 
32,33.
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III). Eight dimethylated and one monomethylated arginine were found in the C-terminal RGG 
box 3 (Fig 3.4 C), whereas the RGG boxes 1 and 2 of EWS protein were almost unmodified. 
Arginines 317, 490, 572, and 575 were not covered by the identified peptides.
Remarkably, we identified several tryptic peptides with dimethylated arginines at their C-
termini although it was reported that trypsin does not cleave after a dimethylated arginine 16,34. 
Table II: 
predicted 
mass
observed 
mass
residue 
numbers
Sequence
m/z 
46
predicted 
mass
observed 
mass
residue 
numbers
Sequence
m/z 
46
1090.51 1090.52 293 to 302 SMSGPDNRGR 1787.82 1787.93 286 to 302 SGPGENRSMSGPDNRGR
1104.52 1104.53 293 to 302 SMSGPDNRGR ü 1801.84 1801.96 286 to 302 SGPGENRSMSGPDNRGR ü
1132.55 1132.58 293 to 302 SMSGPDNRGR ü 1132.55 1132.60 293 to 302 SMSGPDNRGR ü
1373.71 1373.74 293 to 304 SMSGPDNRGRGR ü 1373.71 1373.79 293 to 304 SMSGPDNRGRGR ü
1634.87 1634.93 303 to 317 GRGGFDRGGMSRGGR ü 1023.48 1023.54 303 to 312 GRGGFDRGGM
1067.51 1067.53 303 to 317 GGFDRGGMSR ü 1037.49 1037.56 303 to 312 GRGGFDRGGM ü
1393.71 1393.76 305 to 317 GGFDRGGMSRGGR ü 1065.53 1065.58 303 to 312 GRGGFDRGGM ü
1474.73 1474.77 315 to 330 GGRGGGRGGMGSAGER ü 824.37 824.41 305 to 312 GGFDRGGM ü
1176.55 1176.57 318 to 330 GGGRGGMGSAGER ü 1393.71 1393.79 305 to 317 GGFDRGGMSRGGR ü
988.51 988.53 448 to 455 KPPMNSMR ü 1487.80 1487.89 308 to 321 DRGGMSRGGRGGGR ü
1984.00 1984.11 465 to 486 GMPPPLRGGPGGPGGPGGPMGR ü 1437.67 1437.76 318 to 333 GGGRGGMGSAGERGGF ü
1381.68 1381.59 491 to 503 GGDRGGFPPRGPR ü 1096.48 1096.54 322 to 333 GGMGSAGERGGF
1737.96 1738.03 491 to 506 GGDRGGFPPRGPRGSR ü 1110.50 1110.56 322 to 333 GGMGSAGERGGF ü
1845.95 1846.00 501 to 518 GPRGSRGNPSGGGNVQHR ü 1122.65 1122.71 455 to 464 RGGLPPREGR ü
1507.75 1507.78 504 to 518 GSRGNPSGGGNVQHR ü 1756.86 1756.98 465 to 484 GMPPPLRGGPGGPGGPGGPM
872.42 872.39 564 to 572 GRGGPGGMR ü 1770.88 1771.00 465 to 484 GMPPPLRGGPGGPGGPGGPM ü
849.45 849.49 593 to 600 GGDRGGFR ü 1178.57 1178.65 471 to 484 RGGPGGPGGPGGPM ü
1175.64 1175.67 593 to 603 GGDRGGFRGGR ü 1391.70 1391.77 471 to 486 RGGPGGPGGPGGPMGR ü
1778.88 1778.99 615 to 632 RGGPGGPPGPLMEQMGGR ü 1043.54 1043.59 491 to 500 GGDRGGFPPR ü
897.47 897.50 633 to 641 RGGRGGPGK ü 1761.90 1762.01 572 to 588 RGGRGGLMDRGGPGGMF ü
1265.58 1265.64 576 to 588 GGLMDRGGPGGMF
1279.59 1279.66 576 to 588 GGLMDRGGPGGMF ü
921.42 921.47 580 to 588 DRGGPGGMF ü
1119.57 1119.63 589 to 599 RGGRGGDRGGF ü
1147.61 1147.66 589 to 599 RGGRGGDRGGF ü
1175.64 1175.70 589 to 599 RGGRGGDRGGF ü
1249.66 1249.72 600 to 610 RGGRGMDRGGF ü
1120.59 1120.65 615 to 626 RGGPGGPPGPLM ü
1508.73 1508.85 615 to 629 RGGPGGPPGPLMEQM ü
Table III: 
predicted 
mass
observed 
mass
residue 
numbers
Sequence
m/z 
46
predicted 
mass
observed 
mass
residue 
numbers
Sequence
m/z 
46
1053.49 1053.54 305 to 314 GGFDRGGMSR 1023.48 1023.52 303 to 312 GRGGFDRGGM
1162.54 1162.59 318 to 330 GGGRGGMGSAGER 1423.65 1423.73 318 to 333 GGGRGGMGSAGERGGF
1062.53 1062.60 582 to 592 GGPGGMFRGGR 1437.67 1437.75 318 to 333 GGGRGGMGSAGERGGF ü
1076.54 1076.59 582 to 592 GGPGGMFRGGR ü 1096.48 1096.54 322 to 333 GGMGSAGERGGF
1090.56 1090.61 582 to 592 GGPGGMFRGGR ü 1110.50 1110.54 322 to 333 GGMGSAGERGGF ü
1104.57 1104.61 582 to 592 GGPGGMFRGGR ü 2065.04 2065.02 496 to 516 GFPPRGPRGSRGNPSGGGNVQ
849.43 849.46 593 to 600 GGDRGGFR ü 1105.56 1105.60 589 to 599 RGGRGGDRGGF
1119.58 1119.62 593 to 603 GGDRGGFRGGR ü 1119.58 1119.61 589 to 599 RGGRGGDRGGF ü
1133.59 1133.64 593 to 603 GGDRGGFRGGR ü 1147.61 1147.65 589 to 599 RGGRGGDRGGF ü
1147.61 1147.65 593 to 603 GGDRGGFRGGR ü 1179.58 1179.61 600 to 610 RGGRGMDRGGF
1080.50 1080.54 604 to 614 GMDRGGFGGGR 1221.63 1221.68 600 to 610 RGGRGMDRGGF ü
1094.52 1094.56 604 to 614 GMDRGGFGGGR ü 1167.68 1167.69 630 to 641 GGRRGGRGGPGK ü
1764.86 1764.97 615 to 632 RGGPGGPPGPLMEQMGGR
tryptic peptides chymotryptic peptides
Tryptic and chymotryptic peptides of GST-EWS, methylated with GST-PRMT1, identified by MS/MS. Only methyl-arginine containing pepides 
are listed. Monomethylated arginines are indicated in bold (R), dimethylated arginines are bold and underlined (R). The presence of the 
fragment ion at m/z 46 indicates asymmetric dimethylation.
tryptic and chymotryptic peptides of GST-EWS, methylated with GST-PRMT3, identified by MS/MS. Only methyl-arginine containing pepides 
are listed. Monomethylated arginines are indicated in bold (R), dimethylated arginines are bold and underlined (R). The presence of the 
fragment ion at m/z 46 indicates asymmetric dimethylation.
tryptic peptides chymotryptic peptides
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Thus, arginine dimethylation might reduce, but not prevent cleavage by trypsin and the tryptic 
cleavage does not allow the conclusion that C-terminal arginine residues are unmethylated.
GST-pull down experiments
To investigate whether the in vitro methylation of EWS protein by PRMT1 and 3 reflects 
intracellular interactions, GST-pull down experiments were performed using GST-PRMT1 or 
GST-PRMT3 as baits. Jurkat cells were fractionated as described 30 and GST-PRMT1, GST-
PRMT3, or GST pre-bound to glutathione (GSH)-agarose was added to the nuclear extract, 
which contains the highest amount of EWS protein. Proteins extracted with the GSH-agarose 
were subjected to SDS-PAGE, followed by Western blot analysis as described 30. With GST-
PRMT1 as bait, a large amount of EWS protein was extracted whereas with GST-PRMT3, 
only a weak EWS protein signal was present. With GST alone, no signal of EWS protein was 
detected (Fig. 3.6). Comparable results were obtained using the membrane and the cytosolic 
fraction of Jurkat cells or H9 cells (data not shown).
Discussion
In this study we investigated the methylation characteristics of the type I methyltransferases 
PRMT1 and PRMT3 towards a reference peptide with four methylation sites and towards the 
EWS protein containing 30 potential methylation sites. For both enzymes, the methylation 
reactions were monitored by MALDI-TOF MS. Using MS-based methods for analysing 
protein arginine methylation has the advantage in comparison to measuring incorporation of 
radiolabeled methyl groups, that not only the sites of methylation but also the degree of 
methylation (un-, mono-, or dimethylated) can be followed in a time-dependent manner. 
Methylation of the synthetic reference peptide proved the activity of both recombinant 
Figure 3.6: GST-pull down experiment using 
GST-PRMT1 and GST-PRMT3 as bait. Nuclear 
cell extracts from Jurkat cells (Materials and 
Methods) were used for pull-down experiments. 
Extracted proteins were subjected to SDS-PAGE 
and Western blot analysis using anti-EWS 
antibodies 30. EWS protein from a nuclear cell 
extract (lane 1) was extracted with GST-PRMT1 
(lane 2), with GST-PRMT3 (lane 3), or with GST 
alone (lane 4). Molecular mass markers are 
indicated.
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enzymes GST-PRMT1 and GST-PRMT3 and revealed certain information on their 
mechanisms. GST-PRMT1 adds methyl groups to the peptide with a relatively low catalytic 
efficiency (Table I), values not known so far. The linear time course (Fig. 3.1 C) as well as 
the MS analysis of methylation intermediates by peptide fragmentation (Fig. 3.2 B) 
demonstrate that methylation by GST-PRMT1 takes place in a random order, independent of 
the sequence.
The methylation characteristics of GST-PRMT3 are different. The catalytic efficiency of 
GST-PRMT3 towards GRGG methylation sites is ~12 times higher than that of GST-PRMT1 
(Table I). The reaction velocity decreases, however, on methylation of FRGG sequence motifs 
as revealed by MALDI-TOF MS of partly methylated peptide. Apparently, GST-PRMT3 
differentiates between sequence motifs and methylates arginines within a GRGG motif most 
likely randomly and faster than those in a FRGG motif. Differences due to competitive 
inhibition by AdoHcy, the product of AdoMet, were excluded by inhibition studies. AdoHcy 
inhibits GST-PRMT1 and GST-PRMT3 in a comparable manner (Table I). The kinetic values 
presented here are in the same range as data for the protein methylase I purified from calf 
brain (Kd of 5.9 ?M for AdoMet; Ki of 2.6 ?M for AdoHcy) 
1. The kind of PRMT used in that 
study, however, could not be distinguished at that time.
The present results also demonstrate that GST-EWS protein is efficiently methylated by 
GST-PRMT1. Previous results have shown that at least 29 out of 30 arginines within potential 
methylation sites are dimethylated in vivo 20. No information about the methylation state of 
the 30th arginine (Arg 330) was available, because it could not be detected in that study. Here 
we identified 27 dimethylated arginines after in vitro methylation by GST-PRMT1, among 
them Arg 330. Although one arginine could not be detected and two arginines were found to 
be unmodified, indicating that the methylation reaction was not complete after 3 h, these 
results show that PRMT1, the main cellular methyltransferase in eukaryotic cells 18, 
recognizes most if not all potential methylation sites of the EWS protein.
In contrast to GST-PRMT1, GST-PRMT3 methylated GST-EWS protein less but more 
selectively. Mainly the C-terminal RGG box 3 was found to be methylated almost completely 
whereas the sites in the other two RGG boxes with similar methylation consensus sequences 
were more or less unmodified, even when the reaction time was prolonged or more activity 
units were used (data not shown). Thus, the consensus sequences seem not to be sufficient 
criteria for methylation by GST-PRMT3. Rather structural determinants seem to prevent 
methylation by GST-PRMT3 in some regions, although they are accessible for GST-PRMT1.
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Differential methylation activity of GST-PRMT3 and GST-PRMT1 has already been 
reported 35. PRMT3 was shown to methylate undefined substrates distinct from those of 
PRMT1. Incubation of a hypomethylated yeast rmt1 extract with either PRMT1 or PRMT3 
led to the formation of different methylated products 11. A regulatory effect on the activity of 
PRMT3 might arise from the zinc-finger domain, which among all PRMT is only found in 
PRMT3. High concentrations of zinc (500 ?M) have been reported to inhibit the methylation 
of a recombinant arginine-glycine rich protein (GST-GAR) and hypomethylated RAT1 cell 
extracts by GST-PRMT3. The deletion of the zinc-finger domain in GST-PRMT3 results in 
complete loss of the methylation activity 36. In our study, however, addition of neither zinc 
nor EDTA changed the methylation characteristics of GST-PRMT3 towards the peptide (data 
not shown). Zinc-finger motifs are not only known as modules that trigger protein/DNA or 
protein/RNA interactions but they also interact with each other. C2H2 type zinc-fingers, the 
type that is present in PRMT3, are supposed to be capable of interacting with C2C2 type zinc-
fingers 37. The zinc-finger domain of PRMT3 might be important to recognize its specific 
protein or protein-RNA targets for methylation. The EWS protein indeed contains a C2C2 type 
zinc-finger motif and seems to be capable to bind RNA in its RBD. The interaction between 
the zinc-fingers of PRMT3 and RNA-liganded or RNA-free EWS protein might facilitate the 
arginine methylation of EWS protein. We cannot confirm an influence of zinc since 
methylation of GST-EWS protein with GST-PRMT3 in addition of zinc or EDTA was 
unchanged (data not shown). Recent findings have shown that arginine methylation in vivo is 
a complex process, which requires not only a methyltransferase and a substrate but also 
several cofactors. It was postulated that the type II protein arginine N-methyltransferase JBP1 
associates with pICln and Sm proteins and symmetrically dimethylates the RG domain of Sm 
proteins in a 20S methyltransferase complex, the methylosome 38. The absence of the 
cofactors in the in vitro reactions could thus be responsible for the reduced methylation of 
GST-EWS protein by GST-PRMT3.
CARM1/PRMT4, also a type I methyltransferase, was not considered in this study, because 
the methylated arginine residues of the known substrates like histone H3 12 or the CREB 
binding protein 39 are not within an RGG consensus sequence. By methylating the yeast 
protein Npl3 and GST-GAR, PRMT6 showed a similar substrate specificity like PRMT1 13. In 
our study, however, GST-PRMT6 showed almost no activity towards the reference peptide (1 
?M peptide was incubated with 0.1 ?M GST-PRMT6) and did not methylate the GST-EWS 
protein (2 ?M GST EWS was incubated with 1 ?M GST-PRMT6; data not shown).
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In conclusion, we demonstrated that GST-EWS protein is a new efficient substrate for GST-
PRMT1 but less for GST-PRMT3 in vitro. MS analysis of the methylation process detected 
specific methylation sites of PRMT3, which would not be detectable easily in radiolabeling 
experiments. Most likely also endogenous EWS protein is a strong substrate for PRMT1 but 
less for PRMT3 in vivo as shown by the pull-down experiments. Up to now, only methylated 
endogenous EWS was found in cells, be it in the nucleus, the cytoplasm, or in the membrane 
fraction 20. Unmethylated sites of the EWS protein seem to be rare suggesting that EWS 
protein is methylated immediately after translation, but where and by what PRMT cannot be 
answered yet. It could well be that PRMT3, which is located in the cytosol 11, partly 
methylates EWS protein first and PRMT1 is completing the process in the nucleus. Our 
present findings that nuclear EWS strongly interacts with PRMT1 suggest either that PRMT1 
shows affinity towards methylated EWS protein or certain sites of nuclear EWS protein might 
be still unmethylated. This model fits only, if PRMT1 would be localized in the nucleus, as it 
seems the case for RAT1 cells 11. However, in HeLa cells, PRMT1 was also shown to be 
located in both, the nucleus and the cytosol 13,40. Thus, the place and the sequence of the 
methylation process of the EWS protein remain speculative at the present state of 
investigation as it is whether methylation of EWS protein affects its subcellular localization, 
as reported for proteins like hnRNP 41 or RNA helicase A 42.
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Summary
Protein arginine methylation is a eukaryotic post-translational modification that plays a role 
in transcription, mRNA splicing and transport, in protein-protein interaction, and cell 
signaling. The type I protein arginine methyltransferase (PRMT) 8 is the only member of the 
human PRMT family that is localized at the cell membrane and its endogenous substrates 
have remained unknown as yet.
In this study, we identified more than 20 PRMT8-binding partners in pull-down 
experiments using recombinant PRMT8 as bait followed by mass spectrometric identification 
of the bound proteins. Among the extracted proteins were several heterogeneous nuclear 
ribonucleoproteins (hnRNP), RNA-helicases (DEAD box proteins), the TET-family proteins 
TLS, EWS, and TAFII68, and caprin, which all contain RGG motifs, the preferred 
methylation sequence. They therefore are potential substrates of PRMT8. Further identified 
proteins were actin, tubulin, and heat shock proteins.
We characterized the interaction between PRMT8 and the EWS protein in more detail. 
Although binding of endogenous and recombinant EWS protein to PRMT8 as well as co-
localization in HEK cells was observed, in vitro methylation assays revealed a rather poor 
methyltransferase activity of PRMT8 towards the EWS protein and a synthetic RGG-rich 
reference peptide in comparison to PRMT1. The main interaction site of the EWS protein 
with PRMT8 was determined to be the C-terminal RGG box 3. Remarkably, the complete 
methylation of the EWS protein did not abrogate the binding to PRMT8, pointing to a further 
adapter role of PRMT8 at the cell membrane.
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Introduction
Protein arginine methylation is a eukaryotic post-translational modification catalyzed by 
protein arginine methyltransferases (PRMTs) (1). Currently, nine different human PRMTs are 
known, which all share a highly conserved S-adenosyl-L-methionine (AdoMet) binding site 
and a less conserved substrate binding site. They are classified in type I or type II enzymes, 
that form NG-monomethylarginine (MMA) and asymmetric ω-NG,NG-dimethylarginine 
(ADMA), or MMA and symmetric ω-NG,NG`-dimethylarginine (SDMA), respectively. The 
PRMTs differ in their subcellular localizations, N- and C-terminal extensions, and their 
substrate specificity. Typical substrates of PRMTs are nuclear DNA- or RNA-binding 
proteins like heterogenous nuclear ribonucleoproteins (hnRNPs), spliceosomal proteins, and 
histones. Arginine methylation plays a role in processes like transcriptional control, mRNA 
splicing and -transport, protein-nucleic acids and protein-protein interactions, as well as cell 
signaling (for reviews, see (2,3)). However, the list of identified methylated proteins is still 
growing and for many of them, the role of their methylation is largely unknown.
Human PRMT8 is the type I methyltransferase with the highest sequence similarity to 
PRMT1, the dominant methyltransferase in human cells. The enzyme seems to be expressed 
only in brain tissue and was shown, to associate with the cell membrane upon myristoylation 
(4). The type I methyltransferase activity of recombinant GST-PRMT8 was demonstrated 
towards histone H4 and two recombinant RGG-rich proteins (GST-GAR, GST-Npl1), but 
proved much lower than that of GST-PRMT1 (4). The endogenous substrate proteins of 
PRMT8 as well as its role at the cell membrane are still unknown.
The human Ewing sarcoma (EWS) protein is highly methylated (5) and belongs to the TET-
family (TLS/FUS, EWS, TAFII68) of RNA-binding proteins. It acts as a transcriptional 
coactivator (6,7) and might play a role in splicing or mRNA transport (8). EWS protein-
deficient mice show a high percentage (~90%) of post-natal mortality and the few surviving 
animals fail to develop intact B-lymphocytes and have defects in chromosome pairing during 
meiosis (9). The EWS protein is localized mainly in the nucleus, but minor fractions were also 
detected in the cytosol and associated with the plasma membrane (5,10). Chromosomal 
translocations in the family of Ewing tumors lead to the expression of chimeric fusion 
proteins between the N-terminal transcriptional activation domain (EAD) of the EWS protein 
and DNA-binding domains of different ETS (erythroblastosis virus-transforming sequence) 
transcription factors (11). In the wild-type protein, such transcriptional activity of the 
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oncogenic EAD is repressed by the C-terminal RNA-binding domain (RBD) (12). The RBD 
consists of an RNA-recognition motif (RRM), a putative C2C2 zinc finger, and three arginine-
glycine rich regions (RGG boxes 1-3). All 30 arginines within these RGG boxes were found 
to be asymmetrically dimethylated in vitro and in vivo (5,13).
In the present study we screened for binding partners and potential substrates of PRMT8 to
investigate the role of this membrane-bound methyltransferase. With GST pull-down 
experiments followed by mass spectrometric identification of the bound proteins we could 
show that several nuclear proteins like hnRNPs, the TET family proteins TLS/FUS, EWS, and 
TAFII68, the RNA helicases DDX1 and DDX3X, but also structural proteins like actin and 
tubulin bind to PRMT8. We further characterized the interaction between PRMT8 and the 
EWS protein, which is also associated with the cell membrane, and it turned out, that the 
methyltransferase activity of PRMT8 towards the EWS protein is relatively poor. The 
interaction, however, was maintained independent of the methylation of the EWS protein, 
although its RGG box 3 was determined to be the main interaction site with PRMT8, 
indicating an additional cellular role of PRMT8 than just to act as methyltransferase.
Materials and Methods
Materials – The construct pGEX(SN)-PRMT1 was a generous gift from Dr. Harvey R. 
Herschman (UCLA, Molecular Biology Institute, Los Angeles). GST-PRMT8 (pGEX-6P-1-
vector) and GFP-PRMT8 (pEGFP-N1-vector) were kindly provided by Dr. Mark T. Bedford 
(University of Texas M. D. Anderson Cancer Center, Smithville, Texas). The cDNA of EWS 
was kindly provided by Dr. Olivier Delattre (Institut Curie, Pathologie Moléculaire des 
Cancers, Paris Cedex).
Expression and purification of GST-fusion proteins – GST-PRMT1, GST-PRMT8, and 
GST-EWS were expressed in E.coli XL1-Blue competent cells and purified as described 
(4,13). Each purified protein showed a single major band after SDS-PAGE and Coomassie 
blue staining.
Expression of His-GFP-EWS-myc-His fusion proteins - EWS cDNA was amplified by 
PCR using XhoI-NotI-forward and EcoRI-reverse primers 5'-
TCTCTCGAGCGGCCGCGCCACCATGGCGTCCACGGATTACAGTACC-3' and 5'-
CCGAATTCGTAGGGCCGATCTCTGCGCTCCTG-3', respectively. The PCR product was 
treated with restriction enzymes XhoI and EcoRI and subcloned into pcDNA3.1(-)B/myc-His 
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(Invitrogen) to generate in-frame fusion. To construct the pEGFP-N2-EWS-myc-His vector, 
the EWS-myc-His sequence was amplified by PCR using the above-mentioned XhoI-NoI-
forward primer and SacII-His-reverse primer- 5'-
TCCCCGCGGGGATGATGATGATGATGATGGTCGACG-3', and pcDNA3.1(-)B-EWS-
myc-His expression vector as a template. The resulting fragment was digested with XhoI and 
SacII restriction enzymes, and incorporated into the pEGFP-N2 plasmid (Clontech). The His-
GFP-EWS-myc-His vector was constructed by amplification of the His-GFP fragment from 
pEGFP-N2-EWS-myc-His using the primers NheI-His-forward (5’-
TCTGCTAGCGCCACCATGGCCGTCGACCATCATCATCATCATCAT-3’, and NotI-
GFP-reverse (5’-TGCGTCGCGGCCGCTCTTGTACAGCTCGTCCATGCCGAG-3’) and 
cloning of the PCR product into the pcDNA3.1(-)B-EWS-myc-His plasmid. The truncated 
RBD-YFP-constructs (Fig. 4.5 E) were produced as described (14).
Antibodies – Anti-EWS antibody (against the EWS protein N-terminus, used in 1:5000 
dilution) were kindly provided by Dr. O. Delattre (Institut Curie, Pathologie Moléculaire des 
Cancers, Paris Cedex)). Anti-GFP antibody (N-terminal) from Sigma, which recognizes also 
YFP, was used in a 1:300 dilution, and the anti-His antibody from Sigma (1:2000 dilution) 
was a generous gift of Dr. A. Plückthun (Department of Biochemistry, University of Zurich).
Cell culture, preparation of total cell lysates – Jurkat cells were cultivated in RPMI 
medium at 37°C. To obtain hypomethylated proteins, adenosine-2`,3`-dialdehyde (AdOx, 
from Sigma) was added in a final concentration of 20 µM to the medium and the cells were 
further incubated for 24 h at 37°C. Cells were harvested, washed twice in ice cold PBS buffer 
and lysed for 30 min on ice in lysis buffer A (50 mM Tris, pH 8.0; 200 mM NaCl; 1 mM 
PMSF; 1 mM DTT; 1% Triton-X 100; protease inhibitor mix (Roche)). The lysate was 
centrifuged for 30 min at 13000 rpm and the supernatant was designated as total Jurkat lysate.
Human embryonic kidney (HEK) 293 (T) cells were grown in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% (w/v) of penicillin 
and streptomycin in a humidified 10% CO2 atmosphere at 37ºC. To obtain hypomethylated 
HEK cells, AdOx was added in a final concentration of 20 µM to the medium and the cells 
were further incubated for 24 h. Cells were harvested, washed twice in ice cold PBS and lysed 
in lysis buffer B (??? ??? ?????? ??? ????? ???? ????????? ??? ??? ?–mercaptoethanol; 10% 
glycerol; 1% Triton-X 100; EDTA-free protease inhibitor mix (Roche)) for 30 min on ice. 
After centrifugation for 30 min at 13000 rpm, the obtained supernatant was designated as total 
HEK lysate.
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Transfection, expression, and purification of EWS constructs in HEK cells – HEK cells 
were grown to ~50% confluency for transient transfection through the calcium phosphate 
precipitation method. Expression of the transfected proteins was checked after 20 h by 
fluorescence microscopy. For purification of the EWS constructs, the transfected cells were 
lysed as described above, 10 µl His-SELECT Nickel affinity gel (50% slurry, Sigma) was 
added to 500 µl of the total HEK lysate and incubated for two h at room temperature (RT) 
under constant shaking. The affinity gel was washed twice with lysis buffer B containing 10 
mM imidazole and the bound proteins were eluted specifically using 50 µl of lysis buffer B 
and 250 mM imidazole for 30 min at RT under constant shaking. 
Immunocytochemistry - For protein visualization analysis, HEK cells were grown on glass 
coverslips for 24 h to 40% confluency. For the co-localization assay of the EWS protein and 
PRMT8, the cells were transiently transfected with plasmid expressing PRMT8-GFP (4)
through calcium phosphate precipitation method. The cells were washed 24 h after 
transfection with PBS, fixed and permeabilized with 4% paraformaldehyde (PFA) and 1% 
Triton X-100 for 10 min followed by washing and addition of blocking solution (10% FCS 
and 0.1% glycine in PBS) for 1 h. The cells were incubated first with rabbit anti-C-terminal 
EWS antibody (1:100 dilution, kindly provided by Dr. O. Delattre (Institut Curie, Pathologie 
Moléculaire des Cancers, Paris Cedex)) for 1 h at RT, followed by washing and incubation 
with indocarbocyanine (Cy3)-coupled goat anti-rabbit secondary antibodies (1:500 dilution, 
kindly provided by Dr. P. Sonderegger, Department of Biochemistry, University of Zurich, 
Switzerland) for 1 h at RT. The cells were washed, stained with 4´,6-diamidino-2-phenylindol 
(DAPI,Roche), mounted using Vectashield medium (Vector) onto the glass slides, and 
analyzed by confocal microscopy as described (14) using excitation-emission wavelengths of 
405-470 nm, 488-509 nm and 550-570 nm for DAPI, GFP and Cy3, respectively.
Methylation of the cell extract – Hypomethylated total HEK cell lysate (70 µg of total 
protein) was incubated with GST-PRMT1 (2 µg) or GST-PRMT8 (2 µg) in the presence of 
0.4 µCi S-adenosyl-L-[methyl-3H]methionine (3H-AdoMet, 60 Ci/mmol from a 1 mCi/ml 
stock solution) in PBS for 3 h at 30 °C. The reaction was stopped by the addition of two fold 
Laemmli sample loading buffer and heating at 95°C for five min. The samples were then 
subjected to SDS-PAGE (10% acrylamide gels), the gel was incubated in NAMP 100 
enhancer (Amersham) for 2 h in the dark, the gel was dried and methylated proteins were 
visualized by fluorography.
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GST pull-down – GST or GST-PRMT8 (10 µg) was bound to glutathione-coupled agarose 
(Sigma) for 2 h at RT and the agarose was washed afterwards twice with 100 mM Na-Borate 
and twice with 50 mM Tris, pH 8.0. Either total cell lysate (1 mg of total protein) or purified 
EWS constructs (1-2 µg) was added in the presence of binding buffer (50 mM Tris, pH 8.0; 
100 mM NaCl; 1 mM PMSF; 1 mM DTT; 0.1% Triton X-100; protease inhibitor mix 
(Roche)), and the sample was incubated for one h at RT and one h at 4 °C under constant 
shaking. The agarose was washed three times with binding buffer and bound proteins were 
specifically eluted with 20 mM glutathione / 50 mM Tris, pH 8.0. The eluted proteins were 
separated by SDS-PAGE (10% acrylamide) and analyzed by western blotting or in-gel 
digestion followed by mass spectrometry.
Peptide methylation by GST-PRMT8 – Peptide methylation was performed as described 
(13). Briefly, 2 µM of a synthetic peptide (GRGGFGGRGGFRGGRGG-NH2, from ANAWA 
Biomedical Services & Products) was incubated with 1 µg GST-PRMT8 and 500 µM S-
adenosyl-L-methionine (AdoMet) in 50 mM Tris, pH 8.0 for various time periods at 30°C. 
The methylation reaction was stopped by addition of an equal volume of 50% (v/v) 
acetonitrile (ACN) / 0.1% (v/v) trifluoroacetic acid (TFA). Chymotryptic digestion of the 
peptide was performed in solution with a final concentration of 1 µg chymotrypsin/ml for 15 
min at 30°C. The determination of the kinetic parameters was performed as described (13).
Methylation of recombinant GST-EWS protein – GST-EWS was incubated with GST-
PRMT1 (2 µg) or GST-PRMT8 (2 µg) in the presence of 0.4 µCi 3H-AdoMet (60 Ci/mmol 
from a 1 mCi/ml stock solution) and 500 µM AdoMet in PBS for 3h at 30 °C. The reaction 
was terminated by the addition of 10 µl of two fold Laemmli sample loading buffer to 10 µl 
of the reaction mixture and by heating for 5 min at 95°C. The samples were then subjected to 
SDS-PAGE (10% acrylamide gels), and incubated radioactivity was detected as described 
above. For mass spectrometry analysis, the methylation of GST-EWS was performed with 
unlabeled AdoMet only.
Mass spectrometry (MS) – MS analyses were performed at the Functional Genomics Center 
Zürich (FGCZ) and at the Protein Analysis Unit of the University of Zürich.
To identify the PRMT8-binding proteins from the GST pull-down, the whole gel lane was 
cut into slices and each slice was in-gel digested with trypsin. The tryptic peptides were 
pooled, desalted using C18-ZipTips (Millipore, Bedford, MA), and analyzed by nano-LC-
MSMS using an LTQ-FT (Thermo Electron, Bremen, Germany). Peptides were separated on 
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a nano-HPLC (Eksigent Technologies, Dublin CA) online prior to MS analysis on a home 
made C18 reversed phase column (Magic 3 µm, 100 Å C18 AQ, Michrom, Auburn, CA) using 
an acetonitrile/water system at a flow rate of 200 nl/min. Tandem mass spectra were acquired 
in a data-dependent manner. Typically, 5 MS/MS were performed after each high accuracy 
spectral acquisition range survey. A customized database (38246 entries) comprising the 
human portion (taxonomy ID: 9606) of the UniProt database (http://www.ebi.ac.uk) was 
interrogated using the Mascot search algorithm (15) on an in-house server (FGCZ). For the 
search, three missed trypsin cleavages were allowed. The precursor ion tolerance and 
fragment ion tolerance were set to 2.5 ppm and 0.6 Da, respectively, and oxidized methionine 
was set as variable modification. Only proteins, which were identified in at least two 
independent pull-down experiments were counted as potential interaction partner of PRMT8. 
The MSMS spectra of proteins, whose identification was based only on one or two assigned 
peptides, were checked manually for a correct peak assignment to exclude false positives.
The methylation time course of the peptide was analyzed by MALDI-TOF-MS on a Bruker 
Biflex instrument as described (13). The MSMS analysis of the digested partially methylated 
peptide was performed on a Bruker-Daltonics Ultraflex TOF/TOF II MALDI mass 
spectrometer operated in the positive ion reflector mode with 150 ns as delayed extraction 
time. The nitrogen laser (337 nm) was set to a repetition rate of 50 Hz and the ion acceleration 
voltage was 25 kV. The spectra were calibrated externally.
The in vitro methylated EWS protein was in-gel digested with trypsin or chymotrypsin, the 
peptides were desalted using C18-ZipTips (Millipore, Bedford, MA) and analyzed by LC-
MALDI-TOF/TOF-MS as described (13).
Results
GST pull-down with PRMT8
To identify endogenous interaction partners and potential substrate proteins of PRMT8, 
GST pull-down experiments followed by mass spectrometric analysis of the bound proteins 
were carried out. In the cell, methyl-accepting proteins, the potential substrates of PRMT8, 
are usually already methylated (16) and might not bind anymore to the PRMTs. Unmethylated 
substrate proteins (hypomethylated cell lysate) were obtained by treating Jurkat cells with the 
methyltransferase inhibitor AdOx (adenosine-2´,3´-dialdehyde)(16). Hypomethylated total 
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lysate was added to recombinant GST-
PRMT8 bound to glutathione-coupled 
agarose. After extensive washing, GST-
PRMT8 and its bound interaction 
partners were specifically released with 
glutathione from the agarose and the 
extracted proteins were resolved by SDS-
PAGE (Fig. 4.1). In addition to the 
dominant GST-PRMT8 band at 66 kDa 
and the GST band at 30 kDa (due to 
partial degradation of GST-PRMT8), 
several co-purifying proteins were 
extracted; no dominant protein bands 
except GST are present if the bait was 
recombinant GST. For identification of 
the bound proteins, the whole gel lane 
was cut into slices, each slice was in-gel 
digested with trypsin, the extracted 
peptides were pooled and analyzed by 
LC-MSMS as described in experimental 
procedures. Only proteins, which were 
identified in at least two independent 
pull-down experiments and were not present in any GST-control experiment were counted as 
potential interaction partners of PRMT8.
More than 20 different proteins were identified by mass spectrometry (Table 1). Because 
PRMT1 and PRMT8 are known to form homo- and heterodimers (4), the identification of 
endogenous PRMT1, pulled down by PRMT8, was expected. Among the additional identified 
interaction partners are the three members of the TET-family of RNA-binding proteins 
(TLS/FUS, EWS, and TAFII68), the heterogeneous nuclear ribonucleoproteins (hnRNPs) K, 
U, H3, and A3, the RNA helicases DDX1 and DDX3X, and caprin, which all have RGG 
motifs within their amino acid sequence and thus might be potential substrate proteins of 
PRMT8. But also structural proteins like actin and tubulin, as well as heat shock proteins were 
identified.
Figure 4.1: GST pull-down with PRMT8 as bait. 
Hypomethylated total cell lysate from Jurkat cells 
was used for a pull-down experiment with either 
recombinant GST-PRMT8 or recombinant GST as 
bait. Extracted proteins were resolved by SDS-
PAGE and visualized by Coomassie blue staining 
of the gel. Molecular mass markers in kDa are 
indicated.
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In vitro methylation of the EWS protein by PRMT8
The EWS protein is known to be methylated within its RGG-boxes (13) and beside its 
nuclear localization, the EWS protein was found to be associated to the cell membrane (5). 
Therefore, we investigated whether PRMT8 is able to methylate the EWS protein in vitro. 
Recombinant GST-EWS protein was incubated in the presence of [3H]-AdoMet (S-adenosyl-
L-[methyl-3H]methionine) with either GST-PRMT8 or GST-PRMT1 for 3 h, and the 
incorporation of radiolabeled methyl groups was detected by autoradiography (Fig. 4.2 A). A 
clear band of methylated EWS protein could be seen in the presence of PRMT1, however 
only a faint signal was detected with PRMT8 indicating a very weak methyltransferase 
activity towards the EWS protein. To verify these results and to identify possible methylation 
sites, the EWS protein was methylated by PRMT8 with unlabeled AdoMet and after 
separation of the proteins by SDS-PAGE the EWS protein was in-gel digested either with 
exp. 1 exp. 2
(Q99873) Protein arginine N-methyltransferase 1 41.5 521 378
(P35637) RNA-binding protein TLS/FUS 53.4 586 246 yes
(Q01844) RNA-binding protein EWS 68.5 498 118 yes
(Q92804) RNA-binding protein TAF(II)68 61.8 882 217 yes
(P51991) Heterogeneous nuclear ribonucleoprotein A3 39.6 390 24 yes
(P31942) Heterogeneous nuclear ribonucleoprotein H3 36.9 498 307 yes
(P61978) Heterogeneous nuclear ribonucleoprotein K 50.9 565 1023 yes
(Q9BQ09) Heterogeneous nuclear ribonucleoprotein U 90.5 783 200 yes
(Q92499) ATP-dependent RNA helicase DDX1 (DEAD box protein 1) 82.4 463 140
(O00571) ATP-dependent RNA helicase DDX3X (DEAD box protein 3) 73.2 763 38 yes
(Q9BV09) Caprin (Cytoplasmic activation/proliferation-associated protein 1) 116 423 59 yes
(P60709) Actin, cytoplasmic 1 (Beta-actin) 41.7 782 475
(Q9NY65) Tubulin alpha-8 chain (Alpha-tubulin 8) 50.1 110 352
(P68363) Tubulin alpha-ubiquitous chain (Tubulin K-alpha-1) 50.2 341 168
(P07437) Tubulin beta-2 chain 49.6 475 18
(P38646) Stress-70 protein, mitochondrial precursor 73.7 1607 103
(P08107) Heat shock 70 kDa protein 1 70 425 165
(Q9HAV7) GrpE protein homolog 1, mitochondrial precursor 24.3 264 38
(P11586) C-1-tetrahydrofolate synthase, cytoplasmic 101.6 519 151
(P68104) Elongation factor 1-alpha 1 50.1 322 286
(Q8WXH0) Nesprin-2 (Nuclear envelope spectrin repeat protein 2) 796.4 137 29
(P31327) Carbamoyl-phosphate synthase, mitochondrial precursor (EC 6.3.4.16) 164.9 63 58
Table 1: Identified proteins of the GST-PRMT8 pull-down. Only proteins identified in at least two independent 
experiments are listed with their corresponding mascot scores. The molecular mass (kDa) as well as the presence of 
arginine-glycine rich regions (RGG) within the protein sequece is indicated. 
Mascot score
(primary accession number) protein name RGGkDa
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trypsin or chymotrypsin and the resulting peptides were analyzed by MALDI-TOFTOF-MS. 
All 30 potential methylation sites were covered by the peptides, but only five arginines (R490, 
R572, R596, R603, and R607) were found to be dimethylated (Table 2; Fig. 4.2 B). The 
appearance of the fragment ion at m/z 46 (dimethylamin) in their MSMS spectra confirmed 
the asymmetric dimethylation of these arginines (data not shown) (17,18). Three of them 
(R572, R596, R607) were also present in monomethylated or unmethylated form. All other 
potential methylation sites were found to be unmodified (Table 2).
Methyltransferase activity of PRMT8 towards a peptide
PRMT8 recognized only five arginine residues of the EWS protein as substrate even though 
all 30 arginines, that are known to be methylated within the EWS protein (5,13) are situated in 
highly similar RG(G)-motifs. To test the methylation characteristics and activity of GST-
PRMT8 towards RGG motifs in vitro, we used a synthetic peptide containing four arginine 
methylation sites (GRGGFGGRGGFRGGRGG-NH2) as substrate and analyzed the process of 
methylation as a function of time by mass spectrometry (Fig 4.3 A). This method has been 
proven to be very useful allowing even a quantitative analysis of peptide methylation (13). 
Figure 4.2: In-vitro methylation of the EWS protein by PRMT8. (A) GST-EWS was incubated either 
with GST-PRMT1 or GST-PRMT8 in the presence of 3H-AdoMet for 3h at 30°C, the proteins were 
resolved by SDS-PAGE and radioactivity incorporated in the recombinant EWS-protein (~110 kDa) was 
visualized by autoradiography after five days of exposure at -80°C. (B) Sequence coverage of the mass 
spectrometric analysis of the EWS protein, methylated by GST-PRMT8. The EWS protein band was 
excised from the gel, in-gel digested with either trypsin or chymotrypsin, and the resulting peptides were 
analyzed by MALDI-TOFTOF-MS. Both, the tryptic and chymotryptic peptides cover a large part of the 
EWS protein amino acid sequence (shaded), including all 30 potential methylation sites (3,5). The five 
arginines, which were found to be asymmetrically dimethylated, are shown in bold (R), the 25 
unmethylated potential methylation sites are in italic (R).
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Methylation of the peptide by GST-PRMT8 proceeded very slowly. After one h of incubation, 
the majority of the peptide was still unmethylated. After seven h, the main peak was the four 
times methylated peptide (+56 Da) and it was still the dominant signal even after 22 h. Minor 
fractions of the peptide are also five (+70 Da) and six times (+84 Da) methylated, but a 
complete methylation of the peptide was not achieved. Neither longer incubation times nor 
the addition of fresh PRMT8 completed the methylation of the peptide (data not shown). The 
initial rates at different peptide concentrations indicated a similar Km of PRMT8 and PRMT1 
Calc. 
Mass
Obsrv. 
Mass
± Da
Start 
Seq.
End 
Seq.
Sequence
Ion          
Score
Modification
Ion at     
m/z 46
tryptic peptides
915.46 915.45 -0.01 566 575 GGPGGMRGGR 22 1 Methyl (R)
929.47 929.48 0.01 566 575 GGPGGMRGGR 21 1 di-Methylation (R) yes
778.37 778.36 0.00 582 589 GGPGGMFR 41
835.42 835.41 0.00 593 600 GGDRGGFR 12 1 Methyl (R)
849.43 849.43 0.00 593 600 GGDRGGFR 18 1 di-Methylation (R) yes
1080.50 1080.52 0.02 604 614 GMDRGGFGGGR 24 1 Methyl (R)
1392.69 1392.69 -0.01 601 614 GGRGMDRGGFGGGR 6 2 di-Methylation (R) yes
1750.85 1750.86 0.02 615 632 RGGPGGPPGPLMEQMGGR 64
chymotryptic peptides
1773.80 1773.83 0.02 286 302 SGPGENRSMSGPDNRGR 53
2248.04 2248.06 0.02 286 307 SGPGENRSMSGPDNRGRGRGGF 35
796.34 796.34 0.00 305 312 GGFDRGGM 43
1039.47 1039.47 0.00 305 314 GGFDRGGMSR 20
1679.78 1679.78 0.01 315 333 GGRGGGRGGMGSAGERGGF 77
1686.92 1686.95 0.02 455 470 RGGLPPREGRGMPPPL 43
2087.01 2087.07 0.06 465 487 GMPPPLRGGPGGPGGPGGPMGRM 60
1338.60 1338.61 0.01 472 487 GGPGGPGGPGGPMGRM 83
1133.53 1133.56 0.03 481 492 GGPMGRMGGRGG 14 di-Methylation(R),Ox.(M) yes
1595.83 1595.85 0.03 488 503 GGRGGDRGGFPPRGPR 29
1625.84 1625.86 0.03 491 506 GGDRGGFPPRGPRGSR 20
1633.79 1633.76 -0.03 501 517 GPRGSRGNPSGGGNVQH 76
2186.15 2186.21 0.06 545 565 APKPEGFLPPPFPPPGGDRGR 69
1915.96 1916.00 0.05 552 571 LPPPFPPPGGDRGRGGPGGM 48
1251.56 1251.58 0.02 576 588 GGLMDRGGPGGMF 58
1091.55 1091.56 0.02 589 599 RGGRGGDRGGF 46
1105.56 1105.56 -0.01 589 599 RGGRGGDRGGF 17 Methyl (R)
1119.58 1119.56 -0.02 589 599 RGGRGGDRGGF 31 di-Methylation (R) yes
1165.56 1165.56 0.00 600 610 RGGRGMDRGGF 41
1807.87 1807.88 0.01 611 629 GGGRRGGPGGPPGPLMEQM 117
1750.85 1750.89 0.04 615 632 RGGPGGPPGPLMEQMGGR 73
1538.76 1538.74 -0.02 633 647 RGGRGGPGKMDKGEH 25
Table 2: Identified EWS peptides, which cover all 30 potential methylation sites of the EWS protein. Monomethylated 
arginines are shown in bold (R), asymmetric dimethylated arginines are bold and underlined (R). Five arginines were 
found to be dimethylated, three of them also mono- or unmethylated, whereas 25 arginines were found to be unmodified.
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(1.3 µM and 0.8 µM, respectively) towards this peptide but the catalytic efficiency (kcat/Km) 
was only 1/30 of that of PRMT1 (supplemental Fig. 4.1) (13).
To characterize the methylation pattern, the partly methylated peptide (7 h of incubation) 
was digested with chymotrypsin resulting in the fragments 1-11 (GRGGFGGRGGF; 
Figure 4.3: Methylation of a synthetic peptide by PRMT8. (A) A synthetic peptide (m/z 1563.6, 
GRGGFGGRGGFRGGRGG-NH2) with four arginine methylation sites was incubated with PRMT8 and 
AdoMet at 30°C and analyzed at the indicated time points by MALDI-TOF-MS. Each incorporated 
methyl group leads to a mass increase of 14 Da. The numbers of incorporated methyl groups are indicated 
above the peaks. (B) Methylation of the peptide by GST-PRMT8 was stopped after seven h, the partly 
methylated peptide was digested with chymotrypsin, and the methylation state of the resulting fragments 
(1-11; 12-17) was analyzed by MALDI-TOF-MS. Again, numbers of incorporated methyl groups are 
indicated. The intensive peak at m/z 568 labeled with an asterisk is a signal arising from the matrix (α-
CCA).
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unmodified, 1024.53 Da) and 12-17 (RGGRGG; unmodified, 558.32 Da), each containing 
two arginine residues. Both fragments show the same methylation pattern with mainly two 
incorporated methyl groups (m/z 1052.5 and m/z 586.3), indicating an even distribution of the 
four methyl groups within the peptide (Fig. 4.3 B). To distinguish, whether the two arginines 
of the fragment 1-11 were either both monomethylated, or only one of them was dimethylated, 
or whether a mixture of both cases was present, the dimethylated fragment 1-11 (m/z 1052.5) 
was sequenced by MSMS (supplemental Fig. 4.2). Because of the repetitive amino acid 
sequence, the assignment of the peaks is not always clear as some internal fragments have the 
same mass like b-ions. The dominant peak at m/z 1007.5 (-45 Da of the parent ion) 
corresponds to the neutral loss of dimethylamin, indicating the asymmetric dimethylation of 
the peptide (17,18). Several ions could be uniquely assigned to either dimethylated Arg2 or 
Arg8. The internal ion GGRGG -17 and the ion b7 +28 can only appear if Arg2 is 
dimethylated, whereas the ions a5 -17, b5, and b7 were only possible with a dimethylated Arg8. 
There was no indication for a monomethylation of Arg2 or Arg8. Thus, it seems that PRMT8 
generated mainly random pairs of dimethylated arginines within the peptide.
Methyltransferase activity of PRMT8 towards proteins in a cell lysate
All in all, the in vitro methyltransferase activity of recombinant PRMT8 towards the EWS 
Figure 4.4: Methylation of a cell 
extract by PRMT1 and 8. 
Hypomethylated HEK cell lysate was 
incubated in the presence of 3H-
AdoMet without additional GST-
PRMTs, with GST-PRMT1, or with 
GST-PRMT8 for 3 h at 30°C. Proteins 
were resolved by SDS-PAGE and 
incorporated labeled methyl groups 
were visualized by autoradiography 
after 28 h of exposure at -80°C. 
Molecular mass markers in kDa are 
indicated. The putative assignment of 
the proteins is based on the molecular 
mass of the identified interaction 
partners of PRMT8 (Table 1).
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protein and the peptide was rather poor. To figure out, whether these are just bad substrates or 
recombinant GST-PRMT8 is indeed less active, total cell lysates from HEK cells were used as 
substrate for in vitro methylation in the presence of [3H]-AdoMet. A total lysate from 
hypomethylated HEK cells was incubated with [3H]-AdoMet and GST-PRMT8, GST-PRMT1, 
or without recombinant PRMTs. The proteins were separated by SDS-PAGE and proteins 
with incorporated methyl groups were visualized by autoradiography (Fig. 4.4). The 
endogenous methyltransferases in the hypomethylated cell extract were still active, as 
methylated proteins between 50 kDa and 66 kDa can be detected in the control (Fig. 4.4, lane 
1). The addition of GST-PRMT1 or GST-PRMT8 to the hypomethylated cell extract yielded 
in methylation of several discrete proteins (Fig. 4.4, lanes 2 and 3). Both PRMT8 and PRMT1 
strongly methylated a protein of 116 kDa. Between 55k Da and 80 kDa, the methylation 
pattern of PRMT1 and PRMT8 was comparable, although these bands were less intense than 
in the control. Among the smaller proteins, PRMT8 methylated two additional proteins of ~40 
and 33 kDa, which are almost not methylated by PRMT1. The putative assignment (as 
indicated in Fig. 4.4) is based on the molecular mass of the identified, RGG-containing 
proteins from the pull-down experiments (Table 1).
PRMT8 interacts directly with the EWS protein independent 
of its methylation state
Although pull-down experiments indicated that unmethylated EWS protein interacted with 
PRMT8 (Fig. 4.1), in vitro methylation experiments revealed a rather poor methyltransferase 
activity of PRMT8 towards the EWS protein (Fig. 4.2). Therefore we investigated whether 
also completely methylated EWS protein, which is no more a substrate of PRMT8, still binds 
to PRMT8. Methylated EWS protein was obtained by expressing recombinant His-tagged 
EWS protein (see Experimental procedures) in HEK cells. MS analysis of the purified His-
EWS construct revealed complete methylation of the EWS construct by the endogenous 
PRMTs of the HEK cells. By treating the cells with AdOx prior to transfection, unmethylated 
EWS protein was generated (proven by mass spectrometry). Mass shifts of unmethylated and 
completely methylated representative EWS peptides are shown in the mass spectra (Fig. 4.5
A). The pull-down with GST-PRMT8 was performed with such cell lysates from untreated or 
AdOx-treated HEK cells expressing the EWS construct. Binding of EWS protein was detected 
by western blotting using an EWS specific antibody (Fig. 4.5 B). Both, the unmethylated and 
the methylated His-EWS protein (110 kDa) were extracted by PRMT8 whereas no EWS 
protein was detected in the GST controls.
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Figure 4.5: Identification of the interaction site of the EWS protein with PRMT8. (A) Cut-out of 
MALDI-TOF-MS spectra of the recombinant EWS protein expressed in HEK cells (lower spectrum) or 
HEK cells pre-treated with AdOx to inhibit endogenous methyltransferases (upper spectrum). The 
arrows indicate the mass shifts corresponding to one (+28 Da) or three (+84 Da) dimethylated arginines 
(labeled in bold (R)). (B) HEK cells, pre-treated or not with the methylation inhibitor AdOx, were 
transfected with His-GFP-EWS-myc-His construct, and the total lysate was used for a pull-down with 
GST-PRMT8 as bait. Bound recombinant EWS protein was detected by western blotting using an EWS 
specific antibody. (C) Purified His-GFP-EWS-myc-His was used for a pull-down with GST-PRMT8 as 
bait. Bound recombinant EWS protein was detected by western blotting using an EWS specific 
antibody. Similar amounts of GST-PRMTs were used as shown by coomassie blue staining. (D) Total 
HEK cell lysates, prior transfected with His-GFP-EWS-myc-His or truncated EWS constructs, was 
used for a pull-down with GST-PRMT8 as bait. Bound recombinant EWS constructs were detected by 
western blotting using a His-tag specific antibody.
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PRMT1, a known interaction partner of the EWS protein (13), forms heterodimers with 
PRMT8 (4) and was identified in our pull-down experimets with PRMT8 (Table 1). So the 
interaction between PRMT8 and the EWS protein could be mediated via endogenous PRMT1 
from the cell lysate. Thus, the pull-down experiments were performed by adding the baits 
GST-PRMT8 or GST-PRMT1, pre-bound to GSH-coupled agarose, to purified His-tagged 
EWS protein. PRMT-bound EWS protein was detected by subjecting the eluted proteins to 
SDS-PAGE followed by western blot analysis (Fig 4.5 C). The His-EWS protein bound to 
GST-PRMT1, but also to GST-PRMT8, whereas no binding of the EWS protein was observed 
in the GST control, demonstrating that the EWS protein is a direct interaction partner of 
PRMT8. 
The EWS protein interacts with PRMT8 via its RGG-box 3
To narrow down the region of interaction between the EWS protein and PRMT8, truncated 
His-tagged GFP-EWS constructs, namely the N-terminal transcriptional activation domain 
(EAD, AA 1-299) and the C-terminal RNA-binding domain (RBD, AA 300-656) were 
expressed in HEK cells. The similar transfection efficiency of the two constructs was 
controlled by fluorescence microscopy (data not shown). The total lysates were used for pull-
down experiments with GST-PRMT8 as bait. Bound EWS constructs were detected by 
western blotting using a His-tag-specific antibody (Fig. 4.5 D). Both the full-length EWS 
protein and the RBD interacted with PRMT8 whereas no signal was observed with the EAD. 
None of the constructs bound to the GST control. The RBD consists of three different RGG 
boxes (RGG 1-3), an RNA-recognition motif (RRM), and a putative C2C2 zinc finger motif 
(Fig. 4.5 E). By expressing truncated RBD-YFP fusion constructs (14) and extracting them 
from the cell lysate with GST-PRMT8, the region of interaction within the RBD could be 
identified to be the RGG box 3, as its deletion prevented binding to PRMT8. The deletion of 
RGG box 1, RRM, RGG box 2, or the zinc finger motif did not influence the binding to 
PRMT8 (Fig. 4.5 E).
Figure 4.5 (continued): (E) HEK cells were transfected with RBD-YFP constructs as indicated. The 
total lysate of transfected cells was used for pull-down experiments with GST-PRMT8 as bait. Bound 
recombinant RBD-YFP constructs were detected by western blotting using a GFP specific antibody, 
which recognizes also YFP. Similar amounts of GST-PRMT8 were used for the pull-down experiments 
as shown by coomassie blue staining. Expression of the constructs was shown by analyzing the total 
lysates directly by western blotting (input).
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identification of PRMT1 as a binding partner of PRMT8 confirms the occurrence of 
heterodimers and proves the specificity of the used method. This interaction was also found 
by using GST-PRMT1 as bait, which pulled down endogenous PRMT8 from a HEK cell 
lysate (data not shown), although PRMT8 was as yet thought to be expressed only in brain 
tissue (4).
Further identified interaction partners of PRMT8 were the heterogeneous nuclear 
ribonucleoproteins (hnRNPs) K, U, H3, and A3. HnRNPs function in pre-mRNA splicing and 
mRNA transport and are known to form large complexes in the nucleus (19-21). HnRNP K 
has RGG motifs within its sequence which are known to be methylated by PRMT1 (22,23). A 
large scale proteomic analysis of interaction partners of hnRNP K identified nuclear and 
plasma membrane proteins (24), suggesting a function of hnRNP K in kinase-dependent 
signal transduction. Similarly, hnRNP U, which can be methylated and phosphorylated, was 
found beside its main localization in the nucleus to be attached to the plasma membrane, 
where it is a substrate of ecto-protein kinase (25). Protein arginine methylation is antagonized 
by phosphorylation (26) and vice versa (22), indicating that methylation of proteins at the 
plasma membrane, e.g. by PRMT8, can influence its phosphorylation and therefore its role in 
kinase-dependent signaling.
Caprin (cytoplasmic activation/proliferation-associated protein 1) is a cytoplasmic 
phosphoprotein, which is essential for cellular proliferation (27,28). In the brain, it was 
identified in messenger ribonucleoprotein particles (29). Recently it has been shown, that 
Caprin occurs also in post-synaptic granules in dendrites of neurons, where the RGG-rich C-
terminal region of Caprin selectively binds mRNA (30). Whether caprin is methylated within 
its RGG boxes is not known yet. Considering, that the methylation of the hypomethylated cell 
extract with PRMT8 shows an intensive signal at 116 kDa (Fig. 4.4), it could well be, that 
caprin is a substrate of PRMT8.
Other specific interactors of PRMT8 were the structural proteins actin and tubulin. Tubulin 
fibers are usually used to transport cargo within the cell. It has been shown in neurons, that 
RNA is transported to the dendrites via the microtubules. Thereby, the RNA is bound to 
granules containing among others the RNA helicases DDX1, DDX3X, the EWS protein, 
TLS/FUS, but also hnRNP U (31). All of these proteins were identified in this study as 
PRMT8-interacting proteins. Thus, these proteins might rather co-purify by being part of a 
complex like such RNA-transporting granules than interacting directly with PRMT8. The 
specificity and functionality of the interaction with the remaining identified proteins like heat 
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shock proteins, tetrahydrofolate synthase, elongation factor 1, nesprin, and carbamoyl-
phosphatase synthase needs further elucidation.
The three proteins TLS/FUS, EWS, and TAFII68, which all belong to the TET-family of 
RNA-binding proteins, interact also with PRMT8. These multifunctional nuclear proteins are 
transcriptional co-factors, are involved in splicing (for a review, see (8)), and seem to have a 
function in DNA pairing and recombination (9). They all have RGG-repeats, the preferred 
methylation-motif, within their RNA-binding domain and are therefore potential substrates of 
PRMT8. In neurons, TLS/FUS was shown to localize in granules in the cytoplasm (32), and 
both proteins, TLS/FUS and EWS, were identified in mRNA-transporting granules in 
dendrites (31) as mentioned above. Finally, all TET-family proteins interact with the 
cytoplasmic kinase v-Src (33). As PRMT8 is expressed in particular in brain tissue and 
localized at the plasma membrane (4), an interaction between the TET-family proteins and 
PRMT8 as found in the present study seems feasible. Our results show, that PRMT8 and the 
EWS protein interact directly with each other via the RGG box 3 of the EWS protein (Fig. 4.6 
E), and the co-localization of these two proteins in HEK cells indicate physiological relevance 
of this interaction. The in vitro methylation experiments showed a rather poor 
methyltransferase activity of PRMT8 towards the EWS protein (Fig. 4.2), although other 
proteins of a hypomethylated cell extract could be methylated by recombinant PRMT8 as 
efficient as by recombinant PRMT1 (Fig. 4.4). It seems that the interaction between PRMT8 
and the EWS protein is not an enzyme-substrate interaction, as the binding between them is 
still maintained when the EWS protein is methylated. 
It is known, that arginine methylation can influence protein-protein interaction. Methylation 
of Sam68 prevents its binding to SH3 domains (3), or methylation of hnRNP K inhibits 
binding to the kinase c-Src (22). However, the assembly of the hnRNP complex consisting of 
more than 20 different hnRNPs, most of which are methylated, seem to be independent of 
arginine methylation (20). Here we show for the first time that not only the binding of 
methylated proteins among each other, but also the interaction between a methyltransferase 
and its potential substrate protein may be maintained, although the substrate is completely 
methylated. PRMT8 might therefore act not only as a methyltransferase at the plasma 
membrane. It was shown for several nuclear proteins like nucleolin (34), or the already 
described TET-family proteins, that they are also localized at the cell membrane. However, 
their function and the mechanism, by which they are associated to the membrane is still 
unknown. They have no membrane crossing helices, and post-translational modifications, 
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which facilitate the membrane localization, could not be identified so far for these proteins. 
PRMT8 might therefore act as an adapter protein, which target not only PRMT1 activity, as 
proposed by Lee et al. (4), but also other nuclear proteins to the membrane, although they are 
already methylated.
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Co-localization of PRMT8 and the EWS protein
To visualize the interaction of PRMT8 and the EWS protein, HEK cells were transfected 
with GFP-PRMT8, which shows the typical membrane-associated localization (4) (Fig. 4.6). 
Endogenous EWS protein was visualized within the same cells by immunofluorescence using 
an antibody which recognizes the C-terminus of the EWS protein. Both nuclear and 
extranuclear EWS protein was detected. The merged pictures indicate, that large parts of 
PRMT8 co-localize with the EWS protein at the plasma membrane, supporting the notion of a 
functional intracellular interaction between the EWS protein and PRMT8.
Discussion
PRMT8 is the only membrane-bound member of the human PRMT family (4), but neither 
endogenous substrate proteins nor its particular function at the cell membrane is known so far. 
In the present study, we identified new binding partners and therefore potential substrates of 
PRMT8 by GST pull-down experiments.
More than 20 different proteins which were pulled down with GST-PRMT8 could be 
identified by mass spectrometry (Table 1). Among them was the arginine methyltransferase 
PRMT1. PRMT8 and PRMT1 have been reported to form homo- and heterodimers (4). Our 
Figure 4.6: Co-localization of PRMT8-GFP and endogenous EWS protein. HEK cells were 
transiently transfected with PRMT8-GFP. Endogenous EWS protein is visualized by 
immunofluorescence using a rabbit anti-EWS (C-terminus) primary antibody and indocarbocyanine 
(Cy3)-coupled goat anti-rabbit secondary antibodies. The fluorescent proteins were analyzed by 
confocal microscopy using excitation-emission wavelengths of 405-470 nm, 488-509 nm and 550-570 
nm for DAPI, GFP and Cy3, respectively.
PRMT8 interacts with the EWS protein 79
Supplemental Data
Supplemental Figure 4.1: Kinetics of the peptide methylation by PRMT8. (A) The incorporated 
methyl groups were quantified from the MALDI-TOF-MS spectra at each time point (Fig. 4.3 A) as 
described (13) resulting in a linear initial phase of the peptide methylation. The slope of the linear 
initial phase corresponds to the initial velocity. Complete methylation of the peptide would 
correspond to 8 µM incorporated methyl groups. (B) The initial velocity of the peptide methylation 
was determined using 0.1 µM PRMT8 and varying concentrations of peptide as indicated. (C) Kinetic 
parameters were calculated by hyperbolic curve fitting (SigmaPlot) of (B) as described (13).
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Supplemental Figure 4.2: MSMS-spectrum of the dimethylated peptide fragment 1-11 at m/z 
1052.5. The two methyl groups in this fragment can be situated either at arginine 2 or at arginine 8. Ions 
and internal fragments which can be assigned to the dimethylated Arg2 are labeled in green, those 
which can be assigned to the dimethylated Arg8 are labeled in red. Ions which fit to both cases are 
labeled in black.
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5. Analysis of Ewing Sarcoma (EWS)-binding Proteins: Interaction with 
hnRNP M, U, and RNA-helicases p68/72 within Protein-RNA complexes
Steffen Pahlich, Lilan Quero, Rouzanna P Zakaryan, and Heinz Gehring
In preparation for publication
Summary
The human Ewing Sarcoma (EWS) protein belongs to the TET family of RNA-binding 
proteins and consists of an N-terminal transcriptional activation domain (EAD) and a C-
terminal RNA-binding domain (RBD), which is extensively methylated at arginine residues. 
This multifunctional protein acts in transcriptional co-activation, DNA-recombination, -
pairing and -repair, but also a role in splicing and mRNA transport was reported. The role of 
arginine methylation within these functions is still unclear.
In this study, we performed pull-down experiments with methylated and unmethylated 
recombinant EWS protein as bait, and identified the interacting proteins by mass spectrometry. 
Methylated EWS protein was obtained by co-expression of protein arginine methyltransferase 
(PRMT) 1 and the EWS protein in E.coli. Both, unmethylated and methylated EWS protein 
interact via its C-terminal RNA-binding domain (RBD) with protein-RNA complexes 
consisting of mainly heterogeneous nuclear ribonucleoproteins (hnRNPs) and RNA helicases. 
HnRNP M and U, the RNA-helicases p68 (DDX5) and p72 (DDX17), but also actin and 
tubulin seem to interact directly with the EWS protein.
The interaction of the EWS protein with p68 was confirmed by co-precipitation of the two 
proteins and the RBD of the EWS protein was identified to be the interacting domain. Co-
localization of the EWS protein and the RNA-helicases in the nucleus was visualized by co-
expression of fluorescently labeled EWS protein and p68 or p72 in HEK 293 (T) cells. 
Overexpression of the RNA-helicases relocated the fluorescent EWS protein from the 
nucleoplasm to nucleolar capping structures, a relocalization observed for many proteins, 
when transcription is inhibited. Remarkably, extensive arginine methylations within the RBD 
of the EWS protein, which occur short after or during translation, does not change the 
interaction pattern.
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Introduction
The human Ewings sarcoma (EWS) protein belongs to the TET-family of RNA-binding 
proteins. It consists of an N-terminal transcriptional activation domain (EAD) and a C-
terminal RNA-binding domain. The EAD interacts with calmodulin (42), the splicing factor 1 
(43), protein kinases (42,44), and RNA polymerase II (1), and function as a transcriptional co-
activator (2-4). In Ewings sarcoma, a tumor-associated chromosomal translocation of the EWS
gene results in the expression of fusion proteins of the EWS EAD with DNA-binding domains 
of several ETS transcription factors with transforming potential (5,6). The C-terminal RNA-
binding domain (RBD) of the wild type EWS protein, which represses the tumor-associated 
transcriptional activity of the EAD (7), consists of a RNA-recognition motif (RRM), a 
putative C2C2 zinc finger, and three arginine-glycine rich domains (RGG boxes 1-3). 
Additionally to the transcriptional activity of the EWS protein, a role in splicing and mRNA 
transport is proposed, as the EWS protein interacts with the splicing factors TASR-1 and -2 
(8,9) and YB-1 (10), it co-purifies with the hnRNPs A1 and C1/C2 (11), and it was identified 
in a large scale proteomic analysis of the human spliceosome (12). Recently, a role in DNA 
pairing (13) and recombination was described, as EWS protein-deficient mice fail to develop 
functional B-lymphocytes and have defects in meiosis (14).
The EWS protein is located mainly in the nucleus, directed by its C-terminal nuclear 
localization sequence (15) via transportin (16). Minor fractions of the protein were also 
identified in the cytosol and at the cell membrane. Independent on its subcellular localization, 
the RGG boxes of the EWS protein were found to contain 30 asymmetrically dimethylated 
arginines (17). Arginine methylation is a eukaryotic post-translational modification catalyzed 
by a family of enzymes called protein arginine methyltransferases (PRMTs). They catalyze 
the transfer of a methyl group from the donor S-adenosyl-L-methionine to the guanidino 
nitrogens of the arginine side chain. Methylated arginines are found mainly in RGG-motifs of
RNA-binding proteins like heterogeneous nuclear ribonucleoproteins (hnRNPs), RNA 
helicases, spliceosomal proteins, and histones. Methylated proteins function in transcriptional 
regulation, pre-m-RNA splicing and mRNA-transport, translation, but also a role in signaling 
is proposed (for reviews, see (18,19)). However, for many proteins, like the EWS protein, the 
role of methylation is still not known.
In this study, we performed pull-down experiments with unmethylated and methylated 
recombinant EWS protein as bait to identify interaction partner in dependence of this 
modification. Both, unmethylated and methylated EWS protein interacts with large protein 
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complexes via its RBD. The interaction with these RNAse-sensitive complexes, consisting of 
mainly RNA-binding proteins, could be mediated via RNA-binding of the EWS protein, or 
via the interaction of the EWS protein with hnRNP M, U, and the RNA-helicases p68 / p72.
Co-precipitation and co-localization studies of the EWS protein and p68 did not only confirm 
the interaction, but showed also a relocalization of the EWS protein upon p68 expression from 
the nucleoplasm to the nucleolar periphery. We could show that the EWS protein is 
methylated immediately after or even co-transcriptionally in the cell. The extensive arginine 
methylations within the RBD of the EWS protein are neither needed for subcellular 
localization (15) nor for protein-protein interaction, as demonstrated in this study. Therefore,
a role in RNA-binding, in affecting the activation/repression activity, or even in stabilization
of the EWS protein is proposed.
Materials and Methods
Plasmids and Constructs –The cDNA of EWS was kindly provided by Dr. Olivier Delattre 
(Institut Curie, Pathologie Moléculaire des Cancers, Paris Cedex). GST-p68 and GST-p72 
expression vectors (pEBG2T) for expression in mammalian cells were a generous gift of Dr. 
Frances Fuller-Pace (Division of Pathology & Neuroscience, University of Dundee, UK), and
His-tagged p68 expression vector (pET-30a) was kindly obtained from Dr. Zhi-Ren Liu 
(Department of Animal and Dairy Sciences, Auburn University, Alabama).
Expression of recombinant proteins – GST-EWS was expressed in E.coli as described (21). 
Co-expression of GST-EWS (expression vector pGEX-6p-2) and His-PRMT1 (expression 
vector pET-28c) was done in E.coli XL-blue cells. His-tagged p68 was expressed in E.coli 
BL1-codon plus strain. For expression of His-EWS constructs (15), Human embryonic kidney 
(HEK) 293 T cells were transiently transfected using the calcium phosphate precipitation 
method. Efficient transfection and proper subcellular localization of the different constructs 
was checked by fluorescence microscopy.
Cell culture, preparation of total cell lysates – Jurkat cells were cultivated in RPMI 
medium at 37°C. Cells were harvested, washed twice in ice cold PBS buffer and lysed for 30 
min on ice in lysis buffer A (50 mM Tris, pH 8.0; 200 mM NaCl; 1 mM PMSF; 1 mM DTT; 
1 % Triton-X 100; protease inhibitor mix (Roche)). The lysate was centrifuged for 30 min at 
13000 rpm and the supernatant, designated as total Jurkat lysate, was used for pull-down 
experiments. HEK cells were cultivated in Dulbecco's Modified Eagle's Medium (DMEM) 
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supplemented with 10% (v/v) fetal calf serum (FCS) in a humified 10% (v/v) CO2 atmosphere 
at 37 °C. The cells were cultured to 40% confluency on glass cover slips pre-treated with 
poly-L-Lysin (30 µg/ml) prior to transfection.
Immunostaining and confocal microscopy - 24 h after the transfection, HEK cells were 
washed with PBS, fixed with 4% paraformaldehyd, permeabilized with 1% Triton X-100 and 
incubated for 15 min at RT. The cells were washed three times with PBS, non-specific 
binding sites were blocked in 10% FCS, 0.1% Glycin in PBS, pH 7.4 for one h and washed 
again three times with PBS. Immunostaining was performed using a primary goat anti-GST 
antibody (amersham, 1:2000) and a secondary Cy3-coupled anti-goat antibody (Jackson 
Immuno Research, 1:400). DNA was stained with 4',6-diamidino-2-phenylindol (DAPI,
Roche). Laser-scanning confocal fluorescence microscopy was performed as described (15)
using excitation-emission wavelength of 405-470 nm for DAPI, 514-528 nm for YFP and 
543-570 nm for Cy3. The pictures were merged and co-localized with Adobe Photoshop 8.0 
and Imaris 5.7.0, respectively.
GST pull-down - GST or GST-EWS (10 µg) was bound to glutathione-coupled agarose 
(Sigma) at RT (2 h) and afterwards, the agarose was washed twice with 100mM Na-Borate 
and twice with 50mM Tris, pH 8.0. Total Jurkat cell lysate (1 mg of total protein) was added 
in the presence of binding buffer (50 mM Tris, pH 8.0; 100 mM NaCl; 1 mM PMSF; 1 mM 
DTT; 0.1 % Triton X-100; protease inhibitor mix (Roche)). If indicated, RNase A was added 
to a final concentration of 0.2 mg/ml. The sample was incubated for one h at RT and one h at 
4°C under constant shaking. The agarose was washed three times with binding buffer and 
bound proteins were specifically eluted with 20 mM glutathione / 50 mM Tris, pH 8.0. The 
eluted proteins were separated by SDS-PAGE (10% acrylamide) and analyzed by mass 
spectrometry after in-gel digest or by western blotting.
Mass spectrometry (MS) - MS analyses were performed at the Functional Genomics Center 
Zürich (FGCZ) and at the Protein Analysis Unit of the University of Zürich as described (21).
Briefly, for identification of EWS-binding proteins from the GST pull-down, the whole gel 
lane was cut into slices, the proteins were digested with trypsin, the pooled peptides were 
desalted using C18-ZipTips (Millipore, Bedford, MA), and analyzed by nano-LC-MSMS 
using an LTQ-FT (Thermo Electron, Bremen, Germany) as described (Pahlich et al. submitted 
for publication). MALDI-TOF-MS analysis was performed on a Bruker-Daltonics Autoflex II 
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MALDI mass spectrometer operated in the positive ion reflector mode using α-cyano-
hydroxycinnamic acid (4mg/ml in 70% acetonitrile/0.1% TFA) as matrix.
Results
GST pull-down with EWS protein as bait
To identify endogenous interaction partner of the 
EWS protein, GST pull-down experiments were 
performed. Recombinant GST-EWS protein, 
expressed in E.coli, was bound to proteins were 
specifically eluted with glutathione and subjected to 
SDS-PAGE followed by coomassie blue staining of 
the gel (Fig. 5.1, lane 1). Beside the GST-EWS 
protein band at ~116 kDa, several co-purifying 
protein bands can be seen which are not present when 
GST was used as bait (lane 3). To identify the co-
purified proteins, the whole gel lane was cut into 
slices, each slice was in-gel digested, and the 
resulting peptides were analyzed by LC-MSMS as 
described in materials and methods. More than 30 
different proteins were identified, among them 
mainly RNA-binding proteins like hnRNPs or RNA-
helicases (Table 1), but also the methyltransferase 
PRMT1 and the structural proteins actin, tubulin, and 
vimentin. All identified proteins including their 
Mascot scores are listed in supplemental table 1. Among the identified proteins, the hnRNPs 
A0, A1, D0, G, and H, but also TLS/FUS and TAFII68 were found to contain methylated 
arginine residues (Table 2). The identified methylation sites of hnRNP H (R232) and TAFII68 
(R475, R483, R528, R535, R570) have not been described to our knowledge, whereas the
other identified methylation sites have been reported (20).
Figure 5.1: Pull-down with GST-
EWS protein as bait. Total cell lysate 
from Jurkat cells was used for a pull-
down experiment with recombinant
GST-EWS protein in the absence 
(lane 1) or presence (lane 2) of RNase 
A, or recombinant GST (lane 3) as 
bait. Extracted proteins were resolved 
by SDS-PAGE and visualized by 
Coomassie blue staining of the gel.
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RNase-sensitivity of the complex formation with the EWS proteins
HnRNPs are known to form protein-RNA complexes in the nucleus. To test, whether the 
identified proteins bind directly to the EWS protein or RNA-protein complexes are co-
purified, the cell lysate was pre-treated with RNase A. Subjecting the co-purified proteins to 
SDS-PAGE displays the absence of several proteins (Fig. 5.1, lane 2). MS analysis after in-
gel digestion revealed that almost all RNA-binding proteins except hnRNP M, hnRNP U, and 
the RNA-helicases p68, p72 were absent after RNase treatment (Table 1, supplemental table 
1).
The EWS protein consists of an N -terminal EAD and a C-terminal RBD. To determine, 
which domain is interacting with the RNA-protein complex, pull-down experiments with 
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ANM1_HUMAN (Q99873) Protein arginine N-methyltransferase 1 X X X X
ROA0_HUMAN (Q13151) Heterogeneous nuclear ribonucleoprotein A0 X X
ROA1_HUMAN (P09651) Heterogeneous nuclear ribonucleoprotein A1 X X
ROA2_HUMAN (P22626) Heterogeneous nuclear ribonucleoproteins A2/B1 X X
ROA3_HUMAN (P51991) Heterogeneous nuclear ribonucleoprotein A3 X X
ROAA_HUMAN (Q99729) Heterogeneous nuclear ribonucleoprotein A/B X X
HNRPD_HUMAN (Q14103) Heterogeneous nuclear ribonucleoprotein D0 X X
HNRPF_HUMAN (P52597) Heterogeneous nuclear ribonucleoprotein F X X
HNRPG_HUMAN (P38159) Heterogeneous nuclear ribonucleoprotein G X X
HNRH1_HUMAN (P31943) Heterogeneous nuclear ribonucleoprotein H X X
HNRH2_HUMAN (P55795) Heterogeneous nuclear ribonucleoprotein H' X X
HNRH3_HUMAN (P31942) Heterogeneous nuclear ribonucleoprotein H3 X X
HNRPM_HUMAN (P52272) Heterogeneous nuclear ribonucleoprotein M X X X X
HNRPQ_HUMAN (O60506) Heterogeneous nuclear ribonucleoprotein Q X X
HNRPU_HUMAN (Q00839) Heterogeneous nuclear ribonucleoprotein U X X X X
CIRBP_HUMAN (Q14011) Cold-inducible RNA-binding protein (hnRNP A18) X
FUS_HUMAN (P35637) RNA-binding protein FUS (hnRNP P) X X X
DDX5_HUMAN (P17844) ATP-dependent RNA helicase p68 (DDX5) X X X X
DDX17_HUMAN (Q92841) ATP-dependent RNA helicase p72 (DDX17) X X X X
DDX3X_HUMAN (O00571) ATP-dependent RNA helicase DDX3X X X
DHX9_HUMAN (Q08211) ATP-dependent RNA helicase A X X X
Q8IYE5 (Q8IYE5) ATP-dependent RNA helicase DHX36 X
ACTB_HUMAN (P60709) Actin, cytoplasmic 1 (Beta-actin) X X X X
TBAK_HUMAN (P68363) Tubulin alpha-ubiquitous chain X X
TBB2_HUMAN (P07437) Tubulin beta-2 chain X X X X
VIME_HUMAN (P08670) Vimentin X X
Tab. 1: List of proteins identified in the indicated pull-down experiments. Proteins identified in at 
least two independent experiments are labeled in bold (X), proteins identified in only one 
experiment are labeled in roman (X).
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individual domains in the presence and absence of RNase were performed. The same set of 
hnRNPs and RNA-helicases were identified with the RBD as bait, whereas none of them 
bound to the EAD (data not shown).
GST pull-down with methylated EWS protein as bait
The RBD consists of an RNA-recognition motif (RRM), a putative zinc finger, and three 
RGG rich domains (RGG-boxes 1-3), which contain 30 asymmetrically dimethylated 
arginines (17,21). To investigate the influence of arginine methylation of the EWS protein on 
binding its partners, methylated recombinant EWS protein was used as bait. It was generated 
by co-expression of GST-EWS and His-PRMT1 in E.coli. The GST-EWS protein was
affinity-purified and its methylation state was controlled by MALDI-TOF-MS. All peptides in 
the spectrum, which contained potential arginine methylation sites were found to be 
methylated (Fig. 5.2). Although some incomplete methylated peptides were present, their 
complete methylation was dominant. The EWS protein co-expressed with PRMT1, designated 
here as methylated EWS protein was used for pull-down experiments as described above. A 
very similar set of proteins was extracted and identified when methylated EWS protein was 
used as bait in the presence or absence of RNase A (Table 1, supplemental table 1).
Accession 
number
Protein m/z Peptide sequence Modification
Q13151 hnRNP A0 1968.85 SNSGPYRGGYGGGGGYGGSSF 1 dimethylation (R291)
P09651 hnRNP A1 1422.67 QEMASASSSQRGR 1 dimethylation (R193)
2058.92 SGSGNFGGGRGGGFGGNDNFGR 1 dimethylation (R205)
1340.64 GGNFSGRGGFGGSR 1 dimethylation (R224)
Q14103 hnRNP D0 1334.65 RGGHQNSYKPY 1 dimethylation (R345)
P38159 hnRNP G 770.47 APVSRGR 1 dimethylation (R185)
P31943 hnRNP H 2901.24 RGAYGGGYGGYDDYNGYNDGYGFGSDR 1 dimethylation (R232) new
P35637 TLS/FUS 1762.85 GGRGRGGSGGGGGGGGGGYNR 2 dimethylations (R216, R218)
Q92804 TAF(II)68 2189.91 GGGYGGDRGGGYGGDRGGYGGDR 2 dimethylations (R475, R483) new
1428.62 GGGYGGDRGGYGGDR 1 dimethylation (R475) new
1843.85 SRGGYGGDRGGGSGYGGDR 2 dimethylations (R528, R535) new
1285.59 GGGYGGDRGGYGGK 1 dimethylation (R570) new
Table 2: Methylated peptides of proteins identified in the EWS pull-down. The methylation sites of hnRNP H and TAF(II)68 
are not described so far.
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Figure 5.2: Methylation state of recombinant EWS protein co-expressed with His-PRMT1. GST-
EWS protein was co-expressed with His-PRMT1 in E.coli, the EWS protein was affinity-purified 
using glutathione-coupled agarose, the extracted EWS protein, resolved by SDS-PAGE, was in gel 
digested either with trypsin or chymotrypsin, and the resulting peptides were subjected to MALDI-
TOF-MS analysis. (A) Mass spectrum of the tryptic peptides. All peaks that could be assigned to the 
GST-EWS protein are labeled with a circle. Peptides with potential methylation sites (R) and the 
corresponding methylation state are enlarged. (B) Mass spectrum of the chymotryptic peptides. All 
peaks that could be assigned to the GST-EWS protein are labeled with a circle. Peptides with 
potential methylation sites (R) and the corresponding methylation state are enlarged.
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Interaction of the EWS protein with
RNA helicase p68
In the pull-down experiments, the RNA 
helicase p68 was found to interact with the 
RBD of the EWS protein independent on its 
methylation or RNase A treatment. To 
confirm this interaction, pull-down 
experiments with affinity-purified 
recombinant proteins were performed. 
Purified recombinant GST-RBD was 
incubated with purified recombinant His-
tagged p68 and bound p68 was detected by 
western blotting using anti-His antibodies (Fig. 
5.3). Binding of the p68 was observed with 
both, unmethylated and methylated RBD as 
bait, whereas no p68 could be detected in the 
GST control. These results confirm the 
conclusion made above of a direct interaction 
between the RBD of the EWS protein and the 
RNA-helicase p68 (Table 1).
Co-localization of the EWS protein and RNA helicases p68 and p72
To investigate, whether the EWS protein and the RNA helicases p68 and p72 co-localize in 
cells, HEK 293 (T) cells were co-transfected and YFP-fused EWS protein and GST-p68 or 
GST-p72 were co-expressed. The EWS protein alone shows the expected nuclear localization 
with exclusion from the nucleoli (Fig. 5.4) (15). The RNA-helicases, detected by 
immunostaining using anti-GST antibodies, are also localized in the nucleus with minor 
fractions in the cytosol (Fig. 5.4). Endogenous GST of untransfected cells, which is also 
detected by the antibodies, was not present the nucleus (Fig. 5.4). When co-expressed, large 
parts of the EWS protein and the RNA helicases co-localize in the nucleus. Interestingly, 
upon co-expression of p68 or p72, the EWS protein changes its subnuclear distribution from 
nucleoplasm to the nucleolar periphery (Fig. 5.4).
Figure 5.3: Purified His-p68 was used for a 
pull-down with GST-RBD as bait. 
Recombinant GST-RBD co-expressed with 
His-PRMT1 (methylated RBD) or not 
(unmethylated RBD), pre-bound to 
glutathione-coupled agarose, was incubated 
with purified His-p68. After extensive 
washing, eluted GST-RBD was subjected to 
SDS-PAGE. Bound recombinant His-p68 was 
detected by western blotting using an His-tag-
specific antibody. Similar amounts of GST-
RBD and even more in the GST control were 
used as shown by ponceau staining.
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Figure 5.4: Co-localization of YFP-EWS and p68-GST or p72-GST. HEK cells were transiently 
transfected with YFP-EWS, p68-GST, or p72-GST alone, or co-transfected with YFP-EWS and p68, 
or YFP-EWS and p72-GST. P68-GST and p72-GST were visualized by immunofluorescence using a 
mouse anti-GST primary antibody and Indocarbocyanine (Cy3)-coupled goat anti-rabbit secondary 
antibodies. The fluorescent proteins were analyzed by confocal microscopy using excitation-emission 
wavelengths of 405-470 nm, 488-509 nm and 550-570 nm for DAPI, GFP and Cy3, respectively. The 
pictures were merged using the programs Adobe Photoshop and Imaris. 
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Methylation of the EWS protein occurs in the cytosol
By now, only methylated EWS protein could be found, be it at the cell surface or in the 
nucleus ((17) and own observations). The methyltransferase PRMT1, which methylates the 
EWS protein in vitro (21) was described to be localized either predominantly in the cytosol or 
in the nucleus (22-25). The observed discrepancy might depend on the different cell lines used 
and on different experimental setups, and reflect a dynamic subcellular distribution of PRMT1. 
Whether the EWS protein is methylated first in the cytoplasm and than transported to other 
cell compartments or the methylation takes place in the nucleus, and fractions of the 
methylated protein might be exported and transferred to the cell membrane, was still an open 
question.
To determine, where and when the methylation of the EWS protein occurs, HEK cells were 
transiently transfected with two different EWS constructs, His-EWS or a His-EWS-Y/F
mutant, in which the last tyrosine of the EWS sequence was mutated to phenylalanine (Y922F, 
corresponding to Y656 in the wild type EWS protein). This mutation in the nuclear localization 
signal (C-NLS) of the EWS protein prevents its nuclear import (15). The subcellular 
localization of the constructs were verified by fluorescence microscopy (Fig 5.5 A) 
confirming nuclear localization with exclusion from the nucleoli of His-EWS protein and 
accumulation of the His-EWS-Y/F mutant, designated here as cytoplasmic EWS protein, 
outside of the nucleus (Fig 5.5 B),. Thus, the methylation state of an EWS construct that was 
never in the nucleus can be compared with that present in the nucleus. The His-fusion proteins 
were purified using Ni-affinity agarose and subjected to SDS-PAGE. The EWS constructs, 
which were present as a dominant band at ~ 116 kDa on the coomassie-stained gel, were in-
gel digested and analyzed by mass spectrometry. The peptide at m/z 1275.7 in the spectrum of 
the His-EWS construct covers the intact C-terminus (RQERRDRPY) and is absent in the 
spectrum of the His-EWS-Y/F mutant, whereas the peptide of the mutated C-terminus 
appeared at m/z 1259.7 (RQERRDRPF), confirming the mutation of the EWS C-terminus. In 
both cases, the tryptic and chymotryptic peptides cover large parts of the amino acid sequence 
of the constructs. From the 30 arginines, which were found to be methylated in the EWS 
protein in vivo and in vitro (17,21), 27 were asymmetrically dimethylated in the His-EWS 
wild-type construct, one arginine (R756) was found to be unmodified and the remaining two 
arginines (R569, R730) were not covered by the peptides. A similar methylation pattern was 
observed in the cytoplasmic His-EWS-Y/F mutant, 25 asymmetrically dimethylated arginines 
were detected, one arginine (R756) was found to be monomethylated, one arginine was 
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unmodified (R730), and the remaining three arginines (R569, R838, R841) were not covered 
by the peptides. Peptides in several methylation states were detected in both, nuclear and 
cytoplasmic His-EWS protein, which was not observed in the isolated wild type EWS protein 
Figure 5.5: Methylation state of nuclear and cytoplasmic EWS protein. (A) HEK cells were 
transiently transfected with His-tagged GFP-EWS (nuclear) or GFP-EWS-Y/F (cytoplasmic) and 
fluorescent proteins were analyzed by confocal microscopy using excitation-emission wavelengths of 
405-470 nm and 488-509 nm for DAPI and GFP, respectively. (B) The cells were lysed, the His-
tagged EWS contructs were affinity-purified using Ni-affinity agarose, and extracted EWS protein was 
subjected to SDS-PAGE followed by in-gel digestion and MALDI-TOF-MS analysis. The spectrum 
shows the peptide covering the C-terminus of the EWS protein either without mutation (m/z 1275) or 
with the Y to F substitution (m/z 1259). (C) Peptide coverage of the His-EWS and the His-EWS-Y/F
constructs analyzed by LC-MALDI-TOFTOF-MS. Large parts of the sequence is covered by the 
tryptic (box) or chymotryptic (yellow) peptides. Methylated (R) and dimethylated (R) arginines are 
labeled.
Interaction partner of the EWS protein 93
(own observations). The completely methylated peptides were always the dominant signal in 
the mass spectrum of the His-constructs. This incomplete methylation might be explained by 
the overexpression of the EWS constructs in the cells. All identified peptides including their 
modifications can be found in supplemental table 2.
Discussion
In this study, more than 30 proteins, which were pulled down by the EWS protein, could be 
unequivocally identified. Among them were mainly heterogeneous nuclear ribonucleoproteins 
(hnRNPs), but also RNA-helicases and structural proteins like actin, tubulin, and vimentin. 
Several methylated proteins were found among the identified proteins (Table 2) and for 
hnRNP H and TAFII68, the identified methylation sites have not been, to our knowledge,
described.
HnRNPs are highly abundant nuclear RNA-binding proteins which function in 
transcriptional regulation, mRNA splicing and processing, mRNA transport, and translation 
(26,27). Characteristic structural features of hnRNPs are RNA-recognition motifs (RRM), 
RGG-boxes containing asymmetrically dimethylated arginines, or KH-domains. In the 
nucleus, hnRNPs have been identified to form RNA-dependent complexes, most likely with 
(pre)-mRNA, consisting of ~20 major components with varying composition and 
stoichiometry. Although a function in splicing of several hnRNPs is proposed, they are no key 
elements of the spliceosome (28). The hnRNP-complex (H-complex) rather seems to bind free 
RNA or cover the intron sequences of the pre-mRNA to guide them to degradation in the 
nucleus (29). Here we showed that the EWS protein, methylated or unmethylated, pulled 
down an hnRNP-RNA complex. HnRNPs M and U have been demonstrated to be direct 
binding partners of the EWS protein, as their interaction is mediated even after digestion of 
RNA with RNase A. The C-terminal RBD of the EWS protein contains an RNA-recognition 
motif (RRM) and RGG-boxes with dimethylated arginines, structural features characterizing 
hnRNPs. Binding of the EWS RBD to the H-complex is independent of RBD methylation. As 
methylation of the hnRNPs is also not necessary for assembling the H-complex (30), and the 
EWS-RBD fulfills structural features of hnRNPs, interactions of the RBD, similar to hnRNPs, 
in the H-complex seem likely. However, transcriptional activation domains like the N-
terminal EAD of the EWS protein are absent in hnRNPs. Therefore, the EWS protein might 
target hnRNP-complexes to their place of action in the cell. Considering the fact, that no core 
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proteins of the spliceosome were identified in this study, and that the EAD of the EWS 
protein is able to bind RNA polymerase II, it might function as scaffold protein in targeting 
hnRNPs and other RNA binding proteins to pre-mRNA already during transcription than 
playing a role in splicing.
Another direct interaction partner of the EWS protein, identified in this study, is the RNA-
helicase p68 (DDX5). P68 and its homolog p72 (DDX17) are ATP-dependent RNA helicases 
located in the nucleus and, like the EWS protein, excluded from the nucleoli (31). They were 
identified as part of the human spliceosome in a large scale proteomic analysis (12) and a 
function as a promoter-specific transcriptional co-activator/repressor was reported (32,33). 
Recently, a role in ribosome biogenesis and cell proliferation was observed (34). In this study, 
we could show that the EWS protein interacts directly with p68 via the RBD. In HEK cells, 
we observed co-localization of the EWS protein with both p68 and p72. Interestingly, co-
expression of the EWS protein and p68 or p72 changed the subnuclear distribution from 
nucleoplams, when expressed alone, to an accumulation in the periphery of the nuceoli, when 
co-expressed. Several nuceloplasmic RNA-binding proteins like PSF, p54, p68, TLS/FUS, 
and the EWS protein were identified to relocate to such nucleolar caps under transcriptional 
arrest (35), and a proteomic study of the nucleolar dynamics revealed an upregulation of p68, 
among others, in the nucleolus when transcription was inhibited (36). In that study, ~700 
different proteins were identified as components of the nucleoli, but only one third are 
involved in rRNA biogenesis, an important function of the nucleolus. Therefore, an additional 
role in gene expression was proposed, as the nucleoli might serve as a place, where cellular 
regulators and their activity are sequestered (37) or even degraded, as proposed for the 
transcription factor c-myc (38).
Actin, tubulin, and vimentin were also found to interact with the EWS protein. These 
proteins are highly abundant in the cell and might be extracted unspecifically in such pull-
down experiments, however, they were not found in any GST control pull-down indicating a 
functional relevance of these interactions. It was shown, that the EWS protein is present in 
RNA-transporting granules in dendrites, which transport their cargo via the microtubules (39)
and in quiescent serum-starved cells, the EWS protein forms a net-like structure in the 
cytoplasm and is associated with microtubuli (Thesis of Rouzanna Zakaryan). Beside its 
cytoplasmic localization, actin was shown to be present as a monomer also in the nucleus (40).
The role of the interaction with the EWS protein needs further investigations, but similarly to 
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the interaction of actin with hnRNP U in the nucleus, which is necessary for productive 
transcription of the RNA polymerase II (41), a functional relevance might be likely.
PRMT1, the main arginine methyltransferase in human cells, was also identified in the 
present study to bind to the unmethylated EWS protein in the presence and absence of RNase. 
As PRMT1 efficiently binds to and methylates the EWS protein in vitro and in vivo (21), its 
identification in this pull-down experiments confirms the specificity of the used method. 
Additionally, PRMT1 was found here to interact still with the methylated EWS protein. Even 
if all arginines are methylated, the methyltransferase PRMT1 seems to retain a high affinity 
towards the EWS protein, indicating a further role of PRMT1 as mediator than just being a 
methyltransferase. We could recently show that also PRMT8, a membrane-associated 
methyltransferase with high sequence similarity to PRMT1, interact with both, the methylated 
and unmethylated RGG3 box of the EWS protein (Pahlich et al., submitted for publication). 
Binding partners of the EWS protein, which have been previously reported to interact with 
the EAD of the EWS protein, are the RNA polymerase II (1), calmodulin (42), the splicing 
factor 1 (43), or protein kinases (42,44). They were not found in this study, be it with the full 
length EWS protein or the EAD as bait. The EAD was predicted to be completely 
unstructured, a typical feature of human tumor-related transcription factors (45). Such 
intrinsically disordered proteins can mediate a stable secondary structure only upon ligand 
binding, as shown when CBP binds ACTR (46), or after post-translational modifications such 
as phosphorylation. Recombinant EWS protein or EAD might lack such ligands or 
modifications and therefore also a proper conformation for pulling down known and unknown 
interaction partners.
Additionally, it was demonstrated that the EWS protein is more or less completely
methylated in the cytoplasm, most likely short after translation or even co-translationally, 
before it enters the nucleus. However, the binding of proteins and protein-RNA complexes to 
the EWS protein was not affected by this modification as was the transport of the EWS 
protein to the nucleus (15). Thus, it seems that the methylation of the EWS protein might be 
needed either for RNA binding, for activation/repression activity, or for stabilization, rather 
than being a regulatory element in its function as no unmethylated EWS protein was found in 
the cell and no demethylases are known so far.
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Supplemental Table 1: Proteins identified in GST pull-down experiments. Only proteins, which 
were not identified in any GST-control experiment, are listed. The accession numbers, the protein 
names, and the Mascot scores of the identifications are indicated.
1 2 3 4 5
EWS_HUMAN (Q01844) RNA-binding protein EWS 1158 505 703 555 10647
ANM1_HUMAN (Q99873) Protein arginine N-methyltransferase 1 84 39 663
ROA2_HUMAN (P22626) Heterogeneous nuclear ribonucleoproteins A2/B1 1625 644 566 663
ROA1_HUMAN (P09651) Heterogeneous nuclear ribonucleoprotein A1 1403 498 547 573
HNRH1_HUMAN (P31943) Heterogeneous nuclear ribonucleoprotein H 872 71 368 94
HNRH2_HUMAN (P55795) Heterogeneous nuclear ribonucleoprotein H' 585 255 326
ROA3_HUMAN (P51991) Heterogeneous nuclear ribonucleoprotein A3 895 260 208 321
HNRPU_HUMAN (Q00839) Heterogeneous nuclear ribonucleoprotein U 65 185 164 49 257
HNRPG_HUMAN (P38159) Heterogeneous nuclear ribonucleoprotein G 130 147 222
HNRPM_HUMAN (P52272) Heterogeneous nuclear ribonucleoprotein M 117 464 650
HNRPQ_HUMAN (O60506) Heterogeneous nuclear ribonucleoprotein Q 93 73
HNRPD_HUMAN (Q14103) Heterogeneous nuclear ribonucleoprotein D0 50 110
ROAA_HUMAN (Q99729) Heterogeneous nuclear ribonucleoprotein A/B 32 55
ROA0_HUMAN (Q13151) Heterogeneous nuclear ribonucleoprotein A0 182 73 154
HNRH3_HUMAN (P31942) Heterogeneous nuclear ribonucleoprotein H3 442 98 52 268
HNRPF_HUMAN (P52597) Heterogeneous nuclear ribonucleoprotein F 723 67 21 249
CIRBP_HUMAN (Q14011) Cold-inducible RNA-binding protein (hnRNP A18) 64 48 134
FUS_HUMAN (P35637) RNA-binding protein FUS (hnRNP P) 216 233
DDX5_HUMAN (P17844) Probable RNA-dependent helicase p68 230 255 252
DDX17_HUMAN (Q92841) Probable RNA-dependent helicase p72 104 171 142
DDX3X_HUMAN (O00571) DEAD-box protein 3, X-chromosomal 101 118 112
DHX9_HUMAN (Q08211) ATP-dependent RNA helicase A 105 55 82
Q8IYE5 (Q8IYE5) ATP-dependent RNA helicase DHX36 67 35
SFRS3_HUMAN (P84103) Splicing factor, arginine/serine-rich 3 60 80 64
SFRS9_HUMAN (Q13242) Splicing factor, arginine/serine-rich 9 117 54 133
SFRS1_HUMAN (Q07955) Splicing factor, arginine/serine-rich 1 280 40 123
SMD3_HUMAN (P62318) Small nuclear ribonucleoprotein Sm D3 58 75
SNRPA_HUMAN (P09012) U1 small nuclear ribonucleoprotein A
RBP56_HUMAN (Q92804) TATA-binding protein-associated factor 2N (TAFII68) 63 131
RS18_HUMAN (P62269) 40S ribosomal protein S18 31 31
EF1G_HUMAN (P26641) Elongation factor 1-gamma 33 234
EF1A1_HUMAN (P68104) Elongation factor 1-alpha 1 88 373
Q96PK6 (Q96PK6) Coactivator activator 67 67
ACTB_HUMAN (P60709) Actin, cytoplasmic 1 (Beta-actin) 218 213 78 174 1172
TBAK_HUMAN (P68363) Tubulin alpha-ubiquitous chain 39 53 51 61 691
TBB2_HUMAN (P07437) Tubulin beta-2 chain 62 48 83 1236
VIME_HUMAN (P08670) Vimentin 43 98
RS19_HUMAN (P39019) 40S ribosomal protein S19 29
RL27A_HUMAN (P46776) 60S ribosomal protein L27a 23
RS5_HUMAN (P46782) 40S ribosomal protein S5 83
RS10_HUMAN (P46783) 40S ribosomal protein S10 123
RS7_HUMAN (P62081) 40S ribosomal protein S7 26
RS15A_HUMAN (P62244) 40S ribosomal protein S15a 209
RS16_HUMAN (P62249) 40S ribosomal protein S16 202
RS14_HUMAN (P62263) 40S ribosomal protein S14 31
RS18_HUMAN (P62269) 40S ribosomal protein S18 (Ke-3) (Ke3) 481
RS11_HUMAN (P62280) 40S ribosomal protein S11 51
RL23_HUMAN (P62829) 60S ribosomal protein L23 (Ribosomal protein L17) 29
RS25_HUMAN (P62851) 40S ribosomal protein S25 53
RL38_HUMAN (P63173) 60S ribosomal protein L38 43
Q5VVD0 (Q5VVD0) Ribosomal protein L11 136
RLA1_HUMAN (P05386) 60S acidic ribosomal protein P1 75
RLA0_HUMAN (P05388) 60S acidic ribosomal protein P0 (L10E) 74
RS3_HUMAN (P23396) 40S ribosomal protein S3 303
RS4X_HUMAN (P62701) 40S ribosomal protein S4, X isoform 50
Q3MIH3 (Q3MIH3) Ubiquitin and ribosomal protein L40, 29
Q5VXM2 (Q5VXM2) Mitochondrial ribosomal protein L37 97
Mascot scores
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Supplemental Table 1: (contimued)
1 2 3
EWS_HUMAN (Q01844) RNA-binding protein EWS 1158 471 12334
HNRPM_HUMAN (P52272) Heterogeneous nuclear ribonucleoprotein M 36 466
FUS_HUMAN (P35637) RNA-binding protein FUS (hnRNP P) 121 84
DDX5_HUMAN (P17844) Probable RNA-dependent helicase p68 143 217 54
DDX17_HUMAN (Q92841) Probable RNA-dependent helicase p72 166 211
DDX3X_HUMAN (O00571) DEAD-box protein 3, X-chromosomal 148 241
TBB2_HUMAN (P07437) Tubulin beta-2 chain 392 1752
ACTB_HUMAN (P60709) Actin, cytoplasmic 1 (Beta-actin) 247 1339
RS3_HUMAN (P23396) 40S ribosomal protein S3 289
Q5VXM2 (Q5VXM2) Mitochondrial ribosomal protein L37 (Fragment) 193
RS13_HUMAN (P62277) 40S ribosomal protein S13 180
RLA0_HUMAN (P05388) 60S acidic ribosomal protein P0 (L10E) 174
RS4X_HUMAN (P62701) 40S ribosomal protein S4 166
RS3A_HUMAN (P61247) 40S ribosomal protein S3a 158
RL21_HUMAN (P46778) 60S ribosomal protein L21 137
RL13_HUMAN (P26373) 60S ribosomal protein L13 130
Q6IPX4 (Q6IPX4) RPS16 protein 107
RS9_HUMAN (P46781) 40S ribosomal protein S9 105
Q5VVC8 (Q5VVC8) Ribosomal protein L11 (Fragment) 97
RS7_HUMAN (P62081) 40S ribosomal protein S7 85
RS15_HUMAN (P62841) 40S ribosomal protein S15 (RIG protein) 77
Q5JR95 (Q5JR95) Ribosomal protein S8 76
RL4_HUMAN (P36578) 60S ribosomal protein L4 (L1) 75
RS18_HUMAN (P62269) 40S ribosomal protein S18 (Ke-3) (Ke3) 72
RL3_HUMAN (P39023) 60S ribosomal protein L3 71
Q6IPH7 (Q6IPH7) RPL14 protein (Ribosomal protein L14 variant) 67
RL27A_HUMAN (P46776) 60S ribosomal protein L27a 57
Q4VXZ3 (Q4VXZ3) Ribosomal protein S18 45
RL18A_HUMAN (Q02543) 60S ribosomal protein L18a 40
Q3MIH3 (Q3MIH3) Ubiquitin and ribosomal protein L40 30
RS11_HUMAN (P62280) 40S ribosomal protein S11 30
RL5_HUMAN (P46777) 60S ribosomal protein L5 30
Pull-down with GST-EWS as bait + Rnase A
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Supplemental Table 1: (contimued)
1 2 3
EWS_HUMAN (Q01844) RNA-binding protein EWS 873 3463 8595
ANM1_HUMAN (Q99873) Protein arginine N-methyltransferase 1 98 507 161
FUS_HUMAN (P35637) RNA-binding protein FUS (hnRNP P) 69 127 35
HNRH1_HUMAN (P31943) Heterogeneous nuclear ribonucleoprotein H 76 218 40
HNRPD_HUMAN (Q14103) Heterogeneous nuclear ribonucleoprotein D0 39 73
HNRPG_HUMAN (P38159) Heterogeneous nuclear ribonucleoprotein G 39 193
HNRPM_HUMAN (P52272) Heterogeneous nuclear ribonucleoprotein M 187 976
HNRPU_HUMAN (Q00839) Heterogenous nuclear ribonucleoprotein U 260 118 23
Q5T0N2 (Q5T0N2) Heterogeneous nuclear ribonucleoprotein F 63 252 22
ROA1_HUMAN (P09651) Heterogeneous nuclear ribonucleoprotein A1 182 786
ROA2_HUMAN (P22626) Heterogeneous nuclear ribonucleoproteins A2/B1 179 441
ROA3_HUMAN (P51991) Heterogeneous nuclear ribonucleoprotein A3 130 300
DDX5_HUMAN (P17844) Probable RNA-dependent helicase p68 160 526 61
DDX3X_HUMAN (O00571) DEAD-box protein 3, X-chromosomal 65 452
DHX9_HUMAN (Q08211) ATP-dependent RNA helicase A 17 135
CPSF5_HUMAN (O43809) Cleavage and polyadenylation specificity factor 5 35 41
EF1A1_HUMAN (P68104) Elongation factor 1-alpha 1 63 143 412
EF1G_HUMAN (P26641) Elongation factor 1-gamma 50 43 38
EFTU_HUMAN (P49411) Elongation factor Tu 127 99
H2A1B_HUMAN (P04908) Histone H2A type 1-B 63 58
H4_HUMAN (P62805) Histone H4 22 302 178
MCM7_HUMAN (P33993) DNA replication licensing factor MCM7 33 165
SMD3_HUMAN (P62318) Small nuclear ribonucleoprotein Sm D3 37 54 42
ACTB_HUMAN (P60709) Actin, cytoplasmic 1 (Beta-actin) 115 554 777
TBAK_HUMAN (P68363) Tubulin alpha-ubiquitous chain 109 229 335
TBB2_HUMAN (P07437) Tubulin beta-2 chain 191 577 834
TBB2C_HUMAN (P68371) Tubulin beta-2C chain 188 415 830
VIME_HUMAN (P08670) Vimentin 186 161
ADT2_HUMAN (P05141) ADP/ATP translocase 2 59 122
ATPA_HUMAN (P25705) ATP synthase alpha chain 87 302 478
ATPB_HUMAN (P06576) ATP synthase beta chain 112 37
ATPO_HUMAN (P48047) ATP synthase O subunit 45 95
ENOA_HUMAN (P06733) Alpha-enolase 253 37
G3P_HUMAN (P04406) Glyceraldehyde-3-phosphate dehydrogenase 100 188 108
GRP75_HUMAN (P38646) Stress-70 protein, mitochondrial precursor 64 238
HSP7C_HUMAN (P11142) Heat shock cognate 71 kDa protein 68 63 628
IDHP_HUMAN (P48735) Isocitrate dehydrogenase [NADP] 115 126
LDHB_HUMAN (P07195) L-lactate dehydrogenase B chain 197 69
C1TC_HUMAN (P11586) C-1-tetrahydrofolate synthase, cytoplasmic 59 97
IREB1_HUMAN (P21399) Iron-responsive element-binding protein 1 68 26
RAC2_HUMAN (P15153) Ras-related C3 botulinum toxin substrate 2 precursor 54 54
SERA_HUMAN (O43175) D-3-phosphoglycerate dehydrogenase 83 19
Q5JR95 (Q5JR95) Ribosomal protein S8 177 75
Q5T4L4 (Q5T4L4) Ribosomal protein S27 73 99
Q5VVD0 (Q5VVD0) Ribosomal protein L11 71 86 154
Q5VZM5 (Q5VZM5) Ribosomal protein L21 124 142
RL10A_HUMAN (P62906) 60S ribosomal protein L10a (CSA-19) 94 53
RL13_HUMAN (P26373) 60S ribosomal protein L13 179 77
RL17_HUMAN (P18621) 60S ribosomal protein L17 (L23) 21 117 22
RL18A_HUMAN (Q02543) 60S ribosomal protein L18a 62 47
RL27A_HUMAN (P46776) 60S ribosomal protein L27a 69 70
RL3_HUMAN (P39023) 60S ribosomal protein L3 42 86
RL31_HUMAN (P62899) 60S ribosomal protein L31 25 34
RLA0_HUMAN (P05388) 60S acidic ribosomal protein P0 (L10E) 103 115
RS10_HUMAN (P46783) 40S ribosomal protein S10 106 156
RS11_HUMAN (P62280) 40S ribosomal protein S11 23 127
RS13_HUMAN (P62277) 40S ribosomal protein S13 118 82
RS15A_HUMAN (P62244) 40S ribosomal protein S15a 57 130 212
RS16_HUMAN (P62249) 40S ribosomal protein S16 136 482
RS17_HUMAN (P08708) 40S ribosomal protein S17 86 40
RS18_HUMAN (P62269) 40S ribosomal protein S18 (Ke-3) (Ke3) 27 163 835
RS19_HUMAN (P39019) 40S ribosomal protein S19 21 86 48
RS2_HUMAN (P15880) 40S ribosomal protein S2 (S4) (LLRep3 protein) 38 37
RS3_HUMAN (P23396) 40S ribosomal protein S3 154 179 309
RS4X_HUMAN (P62701) 40S ribosomal protein S4, X isoform 74 141
RS7_HUMAN (P62081) 40S ribosomal protein S7 41 78 72
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Supplemental Table 1: (contimued)
1 2 3
EWS_HUMAN (Q01844) RNA-binding protein EWS 832 1472 9801
ANM1_HUMAN (Q99873) Protein arginine N-methyltransferase 1 666 603
SKB1_HUMAN (O14744) Protein arginine N-methyltransferase 5 73 120
HNRPM_HUMAN (P52272) Heterogeneous nuclear ribonucleoprotein M 34 788
HNRPU_HUMAN (Q00839) Heterogenous nuclear ribonucleoprotein U 125 437
DDX5_HUMAN (P17844) Probable RNA-dependent helicase p68 200 45
EF1A2_HUMAN (Q05639) Elongation factor 1-alpha 2 54 248
EF1B_HUMAN (P24534) Elongation factor 1-beta 101 191
EF1G_HUMAN (P26641) Elongation factor 1-gamma 44 46 209
MCM7_HUMAN (P33993) DNA replication licensing factor MCM7 33 126
SMD3_HUMAN (P62318) Small nuclear ribonucleoprotein Sm D3 91 19
ACTB_HUMAN (P60709) Actin, cytoplasmic 1 (Beta-actin) 143 476 1109
TBAK_HUMAN (P68363) Tubulin alpha-ubiquitous chain 219 282 603
TBB2_HUMAN (P07437) Tubulin beta-2 chain 59 696 753
TBB2C_HUMAN (P68371) Tubulin beta-2C chain 61 659 820
TCPA_HUMAN (P17987) T-complex protein 1 subunit alpha 141 45
ACPH_HUMAN (P13798) Acylamino-acid-releasing enzyme 60 22
ATPA_HUMAN (P25705) ATP synthase alpha chain 114 236
C1TC_HUMAN (P11586) C-1-tetrahydrofolate synthase, cytoplasmic 44 251
DCD_HUMAN (P81605) Dermcidin precursor 32 73
DIRA2_HUMAN (Q96HU8) GTP-binding protein Di-Ras2 21 35
G3P_HUMAN (P04406) Glyceraldehyde-3-phosphate dehydrogenase 40 241 110
HSP7C_HUMAN (P11142) Heat shock cognate 71 kDa protein 108 119 936
IDHP_HUMAN (P48735) Isocitrate dehydrogenase [NADP] 93 83
LDHB_HUMAN (P07195) L-lactate dehydrogenase B chain 192 68
PSD3_HUMAN (O43242) 26S proteasome non-ATPase regulatory subunit 3 25 120
Q5CAQ7 (Q5CAQ7) Heat shock protein HSP 90-alpha 2 277 246
Q6NZ56 (Q6NZ56) Hypothetical protein 40 74
Q9NTK6 (Q9NTK6) Hypothetical protein DKFZp761K0511 429 244
RIB1_HUMAN (P04843) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 25 83
SERA_HUMAN (O43175) D-3-phosphoglycerate dehydrogenase 83 79
TFR1_HUMAN (P02786) Transferrin receptor protein 1 58 48
Q5VVD0 (Q5VVD0) Ribosomal protein L11 47 127
RL13_HUMAN (P26373) 60S ribosomal protein L13 104 83
RL18A_HUMAN (Q02543) 60S ribosomal protein L18a 26 51
RL24_HUMAN (P83731) 60S ribosomal protein L24 80 74
RLA0_HUMAN (P05388) 60S acidic ribosomal protein P0 (L10E) 123 80
RS13_HUMAN (P62277) 40S ribosomal protein S13 74 149
RS15A_HUMAN (P62244) 40S ribosomal protein S15a 113 221
RS16_HUMAN (P62249) 40S ribosomal protein S16 201 170
RS18_HUMAN (P62269) 40S ribosomal protein S18 (Ke-3) (Ke3) 126 223
RS3_HUMAN (P23396) 40S ribosomal protein S3 34 293
RS3A_HUMAN (P61247) 40S ribosomal protein S3a 43 307
RS4X_HUMAN (P62701) 40S ribosomal protein S4, X isoform 112 225
RS9_HUMAN (P46781) 40S ribosomal protein S9 88 78
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